Search Result
Results for "Agonists Inhibitors" in MCE Product Catalog:
1410
Inhibitors & Agonists
| Cat. No. |
Product Name |
Target |
Research Areas |
-
- HY-U00439
-
-
- HY-122737
-
-
- HY-130797
-
-
- HY-103665
-
|
STING agonist-3
|
STING
|
Cancer
|
|
STING agonist-3, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pIC50 of 7.5 and 9.5, respectively. STING agonist-3 has durable anti-tumor effect and tremendous potential to improve treatment of cancer.
|
-
- HY-15394
-
-
- HY-P1333A
-
|
Dynorphin A TFA
|
Opioid Receptor
|
Neurological Disease
|
|
Dynorphin A TFA, an endogenous opioid peptide, is a highy potent kappa opioid receptor (KOR) activator. Dynorphin A TFA also serve as an agonist for other opioid receptors, such as mu (MOR) and delta (DOR).
|
-
- HY-P1334A
-
-
- HY-N2548
-
-
- HY-135280
-
-
- HY-124697
-
|
BMP signaling agonist sb4
|
TGF-β Receptor
|
Cancer
|
|
BMP signaling agonist sb4 is a potent benzoxazole bone morphogenetic protein 4 (BMP4) signaling agonist with a EC50 value of 74 nM, activates BMP signaling by stabilizing intracellular p-SMAD-1/5/9. BMP signaling agonist sb4 activates BMP4 target genes (inhibitors of DNA binding, Id1 and Id3) canonical BMP signaling.
|
-
- HY-12745A
-
|
Nalfurafine hydrochloride
TRK-820 hydrochloride
|
Opioid Receptor
|
Neurological Disease
|
|
Nalfurafine hydrochloride (TRK-820 hydrochloride) is a potent selective and orally active G protein-biased kappa opioid receptor (KOR)-agonist with high translational potential. Nalfurafine hydrochloride (TRK-820 hydrochloride) enhances the therapeutic potential of MOR-targeting analgesics, has the potential for uremic pruritis treatment.
|
-
- HY-12745
-
|
Nalfurafine
TRK-820
|
Opioid Receptor
|
Neurological Disease
|
|
Nalfurafine (TRK-820) is a potent selective and orally active G protein-biased kappa opioid receptor (KOR)-agonist with high translational potential. Nalfurafine (TRK-820) enhances the therapeutic potential of MOR-targeting analgesics, has the potential for uremic pruritis treatment.
|
-
- HY-10019
-
|
Varenicline
CP 526555
|
nAChR
|
Neurological Disease
|
|
Varenicline (CP 526555) is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC50 value of 2.3 μM. Varenicline is a full agonist for α3β4 and α7 nAChRs with EC50 values of 55 μM and 18 μM, respectively. Varenicline is a nicotinic ligand based on the structure of cytisine, has the potential for smoking cessation treatment.
|
-
- HY-131005
-
-
- HY-125996
-
|
NR1H4 activator 1
|
FXR
|
Inflammation/Immunology
|
|
NR1H4 activator 1 is a potent and selective Famesoid X Receptor (FXR) agonist, extracted from patent WO2018152171A1, example 4. NR1H4 activator 1 shows strong FXR agonistic potency with a EC50 value of 1 nM in a Human FXR (NR1H4) Assay. NR1H4 activator 1 has the potential for treatment of gastrointestinal disease.
|
-
- HY-133112
-
-
- HY-121879
-
-
- HY-101198
-
|
Clobenpropit dihydrobromide
|
Histamine Receptor
|
Cancer
Neurological Disease
|
|
Clobenpropit dihydrobromide is a potent histamine H3R antagonist/inverse agonist with a pEC50 of 8.07 for histamine H3LR. Clobenpropit dihydrobromide acts as partial agonist at histamine H4 receptors (Ki 13 nM). Clobenpropit dihydrobromide also binds to serotonin 5-HT3 receptors (Ki 7.4 nM) and α2A/α2C adrenoceptors (Ki 17.4/7.8 nM). Clobenpropit dihydrobromide increases apoptosis.
|
-
- HY-100369A
-
|
DMCM hydrochloride
|
GABA Receptor
|
Neurological Disease
|
|
DMCM hydrochloride is a nonselective full inverse agonist of benzodiazepine. DMCM shows bnding afinity at human recombinant GABAA αxβ3γ2 receptor subtypes with Kis of 10 nM, 13 nM, 7.5 nM, 2.2 nM for α1, α2, α3, and α5 receptors, respectively.
|
-
- HY-129527
-
|
GNE-9278
|
iGluR
|
Neurological Disease
|
|
GNE-9278 is a highly selective positive allosteric modulator of NMDAR that acts at the GluN1 transmembrane domain (TMD). GNE-9278 acts on activated NMDARs to increase peak current and agonist affinity.
|
-
- HY-19373
-
-
- HY-16787
-
|
ICA-121431
|
Sodium Channel
|
Cardiovascular Disease
|
|
ICA-121431 is a nanomolar potent and broad-spectrum voltage-gated sodium channel (Nav) blocker, shows equipotent selectivity for human Nav1.1 and Nav1.3 subtypes with IC50 values of 13 nM and 23 nM, respectively. ICA-121431 shows less potent inhibition of Nav1.2 (IC50=240 nM) and 1,000 fold selectivity against Nav1.4, Nav1.6, and the TTX-resistant human Nav1.5 and Nav1.8 channels (IC50s >10 µM).
|
-
- HY-103476
-
|
Ro15-4513
|
GABA Receptor
|
Neurological Disease
|
|
Ro15-4513, imidazobenzodiazepinone derivative, is a partial inverse agonist of benzodiazepine receptor (BZR). Ro15-4513 is a potent ethanol antagonist. Ro15-4513 has anti-anxiety effect.
|
-
- HY-17038A
-
|
Agomelatine hydrochloride
S-20098 hydrochloride
|
Melatonin Receptor
5-HT Receptor
|
Neurological Disease
|
|
Agomelatine hydrochloride (S-20098 hydrochloride) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively. Agomelatine hydrochloride is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively.
|
-
- HY-17038
-
|
Agomelatine
S-20098
|
Melatonin Receptor
5-HT Receptor
|
Neurological Disease
|
|
Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively.
|
-
- HY-P2161
-
|
TAK-683
|
Others
|
Cancer
|
|
TAK-683 is a potent full KISS1 receptor (KISS1R) agonist (IC50=170 pM) with improved metabolic stability. TAK-683 is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC50 values of 0.96 nM and 1.6 nM for human and rat, respectively. TAK-683 depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer.
|
-
- HY-17038B
-
|
Agomelatine (L(+)-Tartaric acid)
S-20098 L(+)-Tartaric acid
|
Melatonin Receptor
5-HT Receptor
|
Neurological Disease
|
|
Agomelatine L(+)-Tartaric acid (S-20098 L(+)-Tartaric acid) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively. Agomelatine L(+)-Tartaric acid is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively.
|
-
- HY-U00439A
-
|
Protein kinase inhibitors 1 hydrochloride
(E)-5-((2-Oxo-6'-(piperazin-1-yl)-1,2-dihydro-[3,3'-bipyridin]-5-yl)methylene)thiazolidine-2,4-dione hydrochloride
|
DYRK
|
Cancer
|
|
Protein kinase inhibitors 1 hydrochloride is a potent HIPK2 inhibitor, with IC50s of 136 and 74 nM for HIPK1 and HIPK2, and a Kd of 9.5 nM for HIPK2.
|
-
- HY-100991
-
|
FG 7142
ZK 39106; LSU-65
|
GABA Receptor
|
Neurological Disease
|
|
FG 7142 (ZK 39106; LSU-65), a non-selectively benzodiazepine inverse agonist, has high affinity for the α1 subunit-containing GABAA receptor (Ki=91 nM). FG 7142 (ZK 39106; LSU-65) also modulates GABA-induced chloride flux at GABAA receptors expressing the α1 subunit (EC50= 137 nM). FG 7142 (ZK 39106; LSU-65) can increase tyrosine hydroxylation and cause upregulation of β-adrenoceptors in mouse cerebral cortex.
|
-
- HY-W012037
-
|
8-Hydroxyquinoline hemisulfate
8-Quinolinol hemisulfate
|
Bacterial
Antibiotic
|
Infection
|
|
8-Hydroxyquinoline hemisulfate (8-Quinolinol hemisulfate) is a monoprotic bidentate chelating agent, exhibits antiseptic, disinfectant, and pesticide properties, functioning as a transcription inhibitor.
|
-
- HY-135813
-
|
LtaS-IN-1
|
Bacterial
|
Infection
|
|
LtaS-IN-1 (compound 1771) is a potent small-molecule inhibitor of Lipoteichoic acid (LTA) synthesis in multidrug-resistant (MDR) E. faecium and by altering the cell wall morphology. LtaS-IN-1 alone inhibits Enterococcus.spp 28 strains with varying MIC values ranging from 0.5 μg/mL to 64 μg/mL. LtaS-IN-1 combination with antibiotics abolishs multidrug-resistant E. faecium growth almost completely.
|
-
- HY-125957
-
|
A-3 hydrochloride
|
PKA
Casein Kinase
CaMK
PKC
|
Others
|
|
A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases. It against PKA (Ki=4.3 µM), casein kinase II (Ki=5.1 µM) and myosin light chain kinase (MLCK) (Ki=7.4 µM). A-3 hydrochloride also inhibits PKC and casein kinase I with Ki values of 47 µM and 80 µM, respectively.
|
-
- HY-101918
-
|
DS-1040 Tosylate
|
Others
|
Cardiovascular Disease
|
|
DS-1040 Tosylate is an orally active, selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50s of 5.92 nM and 8.01 nM for human and rat TAFIa. DS-1040 Tosylate is a fibrinolysis enhancer for thromboembolic diseases.
|
-
- HY-18728
-
-
- HY-15583
-
-
- HY-101232
-
|
Tiotidine
ICI 125211
|
Histamine Receptor
|
Cardiovascular Disease
|
|
Tiotidine (ICI 125211) is a potent and selective antagonist of histamine H2-receptor (pA2=7.3-7.8 for guinea-pig right atrium). Tiotidine has low affinity for both the H1 and the H3 receptors.
|
-
- HY-122470
-
|
Stampidine
|
Reverse Transcriptase
HIV
|
Infection
|
|
Stampidine is a nucleoside reverse transcriptase inhibitor (NRTI) with potent and broad-spectrum anti-HIV activity. Stampidine inhibits the laboratory HIV-1 strain HTLVIIIB (B-envelope subtype) and primary clinical isolates with IC50s of 1 nM and 2 nM, respectively. Stampidine also inhibits NRTI-resistant primary clinical isolates and NNRTI-resistant clinical isolates with IC50s of 8.7 nM and 11.2 nM, respectively.
|
-
- HY-14234
-
-
- HY-13581A
-
-
- HY-11007
-
|
GNF-2
|
Bcr-Abl
SARS-CoV
|
Cancer
|
|
GNF-2 is a highly selective, allosteric, non-ATP competitive inhibitor of Bcr-Abl. GNF-2 inhibits Ba/F3.p210 proliferation with an IC50 of 138 nM .
|
-
- HY-131145
-
-
- HY-123943
-
|
STING agonist-4
|
STING
|
Cancer
|
|
STING agonist-4 is an stimulator of Interferon Genes (STING) receptor agonist with an apparent inhibitory constant (IC50) of 20 nM. STING agonist-4 is a two symmetry-related amidobenzimidazole (ABZI)-based compound to create linked ABZIs (diABZIs) with enhanced binding to STING and cellular function.
|
-
- HY-112921B
-
-
- HY-112921A
-
-
- HY-126321
-
|
RORγt agonist 1
|
ROR
|
Cancer
|
|
RORγt agonist 1 (compound 14) is a potent, orally bioavailable RORγt agonist with an EC50 of 20.8 nM. RORγt agonist 1 showes high metabolic stability, improved aqueous solubility and excellent mouse PK profile. RORγt agonist 1 is a potential candidate of RORγt agonist for cancer immunotherapy.
|
-
- HY-133777
-
-
- HY-100699
-
-
- HY-118539
-
-
- HY-112921
-
-
- HY-107399
-
-
- HY-17354A
-
-
- HY-17354
-
-
- HY-P0236A
-
-
- HY-114400
-
-
- HY-B2245
-
-
- HY-112597
-
-
- HY-110304
-
-
- HY-19574
-
-
- HY-103665A
-
|
STING agonist-3 trihydrochloride
|
STING
|
Cancer
|
|
STING agonist-3 trihydrochloride, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pEC50 of 7.5 and 9.5, respectively. STING agonist-3 trihydrochloride has durable anti-tumor effect and tremendous potential to improve treatment of cancer.
|
-
- HY-135400
-
-
- HY-111358
-
-
- HY-100120
-
-
- HY-126293
-
|
Apelin agonist 1
|
Others
|
Cardiovascular Disease
|
|
Apelin agonist 1 is an oral selective apelin agonist AM-2995, a agonist of the APJ (APLNR, angiotensin receptor like-1) receptor, may be used in the treatment of cardiovascular conditions. Apelin agonist 1 is extracted from patent WO 2018097944 (210.0), Example 210.0.
|
-
- HY-13239
-
-
- HY-131105S
-
-
- HY-P1738
-
-
- HY-109131
-
-
- HY-128855
-
|
Talsaclidine
|
mAChR
|
Neurological Disease
|
|
Talsaclidine is a muscarinic agonist with preferential neuron-stimulating properties. Talsaclidine is a full agonist at the M1 subtype, and as a partial agonist at the M2 and M3 subtypes.
|
-
- HY-107688A
-
|
UB-165 fumarate
|
nAChR
|
Neurological Disease
|
|
UB-165 fumarate is a nAChR agonist, being a full agonist of the α3β2 isoform and a partial agonist of the α4β2* isoform, with a Ki value of 0.27 nM for nicotine binding in rat brain.
|
-
- HY-102053
-
-
- HY-135399
-
-
- HY-P0078
-
-
- HY-10020
-
|
Varenicline Hydrochloride
CP 526555 hydrochloride
|
nAChR
|
Neurological Disease
|
|
Varenicline Hydrochloride (CP 526555 hydrochloride) is a high affinity, selective α4β2 nicotine acetylcholine receptor (nAChR) partial agonist and full α7 nAChR agonist. Varenicline Hydrochloride is also a potent partial agonist of α6β2 nAChR in striatum of rats with a Ki value of 0.12 nM.
|
-
- HY-131104S
-
-
- HY-111748
-
-
- HY-P1144
-
-
- HY-101039A
-
-
- HY-19673A
-
-
- HY-131104AS
-
-
- HY-B0976
-
-
- HY-111353
-
-
- HY-P1144A
-
-
- HY-103039
-
-
- HY-100699S
-
-
- HY-112679
-
-
- HY-100087
-
-
- HY-B1532
-
-
- HY-B1833
-
-
- HY-100810
-
-
- HY-108415
-
-
- HY-103083
-
-
- HY-112185
-
-
- HY-U00395
-
-
- HY-B0976A
-
-
- HY-114321
-
-
- HY-100469
-
|
LXRβ agonist-2
|
LXR
|
Cardiovascular Disease
|
|
LXRβ agonist-2 is a highly potent and β-selective liver X receptor (LXRβ) agonist with EC50 of 7 nM, displays 28.5-fold selectivity over LXRα (EC50=200 nM) and used in the treatment of atherosclerosis.
|
-
- HY-13288
-
-
- HY-111359
-
-
- HY-19522
-
|
Seladelpar
MBX-8025
|
PPAR
|
Metabolic Disease
|
|
Seladelpar (MBX-8025) is an orally active, potent (50% effect concentration EC50 2 nM), and specific PPAR-δ agonist.
|
-
- HY-U00340
-
|
PPAR agonist 1
|
PPAR
|
Metabolic Disease
|
|
PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.
|
-
- HY-107743
-
|
Naloxone benzoylhydrazone
NalBzoH
|
Opioid Receptor
|
Neurological Disease
|
|
Naloxone benzoylhydrazone (NalBzoH) is a mixed agonist/antagonist. Naloxone benzoylhydrazone is a prototypic κ3-opioid receptor agonist, and a partial agonist at the cloned μ and δ opioid receptors, and an antagonist at opioid-like NOP receptors. Naloxone benzoylhydrazone has potently analgesia effect.
|
-
- HY-128353
-
|
ROR agonist-1
|
ROR
|
Inflammation/Immunology
|
|
ROR agonist-1 is a potent and orally bioavailable inverse agonist of the retinoic acid receptor-related orphan receptor C2 (RORC2), inhibition of IL-17A production from human primary TH 17 cells with a pIC50 of 7.5.
|
-
- HY-42068
-
-
- HY-B1829A
-
-
- HY-B0556A
-
-
- HY-101717
-
-
- HY-17405
-
-
- HY-U00281
-
-
- HY-U00227
-
-
- HY-111583
-
|
RXFP3/4 agonist 1
|
Others
|
Metabolic Disease
|
|
RXFP3/4 agonist 1 is an agonist of relaxin family peptide 3/4 receptor (RXFP3/4), with EC50s of 82/2 nM, respectivley. RXFP3/4 agonist 1 increases food intake in rats.
|
-
- HY-130243
-
|
RORγt Inverse agonist 6
|
ROR
|
Inflammation/Immunology
|
|
RORγt Inverse agonist 6 (compound 43) is a RORγt inverse agonist for the treatment of Th17-driven autoimmune diseases. RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in vivo.
|
-
- HY-19711
-
|
STING agonist-1
G10
|
STING
Virus Protease
|
Infection
|
|
STING agonist-1 (G10) is human-specific STING agonist that elicits antiviral activity against emerging Alphaviruses. G10 potently blocks replication of Alphavirus species Venezuelan Equine Encephalitis Virus (VEEV) with IC90 of 24.57 μM.
|
-
- HY-100234A
-
-
- HY-12405
-
-
- HY-108711
-
|
GPR120 Agonist 1
|
GPR120
|
Metabolic Disease
|
|
GPR120 Agonist 1 is a potent and selective GPR120 agonist, and possesses promising antidiabetic effect and good safety profile to be a development candidate.
|
-
- HY-136608
-
-
- HY-136609
-
-
- HY-100234
-
-
- HY-114411
-
-
- HY-B1540
-
-
- HY-U00315
-
-
- HY-U00205
-
-
- HY-P1000
-
-
- HY-10473
-
-
- HY-U00123
-
-
- HY-19065
-
-
- HY-P0187
-
-
- HY-17416A
-
-
- HY-B0664
-
-
- HY-N1415
-
-
- HY-101265
-
|
S1p receptor agonist 1
|
LPL Receptor
|
Inflammation/Immunology
|
|
S1p receptor agonist 1 is a potent and orally active S1P receptor agonist, exhibits an activity of inducing S1P1 internalization (EC50=9.83 nM). S1p receptor agonist 1 has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis). S1p receptor agonist 1 is extracted from patent WO2015039587A1, Compound 2.
|
-
- HY-13660
-
-
- HY-109136
-
|
Runcaciguat
|
Guanylate Cyclase
|
Cardiovascular Disease
|
|
Runcaciguat is an orally active stimulator of soluble guanylate cyclase, and is used in the research of cardiovascular and renal diseases combined with selective partial adenosine A1 receptor agonists.
|
-
- HY-P1504
-
-
- HY-12835
-
-
- HY-B0163
-
|
Detomidine
|
Adrenergic Receptor
|
Neurological Disease
Endocrinology
|
|
Detomidine produce dose-dependent sedative and analgesic effects, is a nonnarcotic, synthetic α2-adrenergic agonist
Target: α2-adrenergic agonist
Detomidine is an imidazole derivative and α2-adrenergic agonist, used as a large animal sedative, primarily used in horses.
|
-
- HY-B0163A
-
-
- HY-U00391
-
-
- HY-P1504A
-
-
- HY-U00396
-
-
- HY-10013
-
|
Taranabant
MK-0364
|
Cannabinoid Receptor
|
Metabolic Disease
|
|
Taranabant is a highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist that inhibits the binding and functional activity of various agonists, with a binding Ki of 0.13 nM for the human CB1R in vitro.
|
-
- HY-W002116
-
-
- HY-129657
-
|
GLP-1 receptor agonist 4
|
Glucagon Receptor
|
Metabolic Disease
|
|
GLP-1 receptor agonist 4 is a glucagon-like peptide-1 receptor (GLP-1R) agonist extracted from patent WO2009111700A2, compound 87, has an EC50 of 64.5 nM. GLP-1 receptor agonist 4 can be used in the research for treatment of diabetes.
|
-
- HY-114310
-
|
VDR agonist 1
|
VD/VDR
Apoptosis
|
Cancer
|
|
VDR agonist 1 (compound 28) is a nonsteroidal Vitamin D receptor (VDR) agonist, with an IC50 of 690 nM in MCF-7 cells. VDR agonist 1 arrests the cell cycle through the up-regulation of p21 and p27, promotes apoptosis by increasing the expression of BAX and decrease the expression of Bcl-2.
|
-
- HY-P2278
-
-
- HY-100327
-
-
- HY-U00066
-
-
- HY-A0173
-
-
- HY-P1013
-
-
- HY-A0129
-
-
- HY-100380
-
-
- HY-107901
-
|
Pparδ agonist 1
|
PPAR
|
Metabolic Disease
Cardiovascular Disease
|
|
Pparδ agonist 1 is a PPAR-δ agonist, with an EC50 of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases.
|
-
- HY-108566
-
-
- HY-B0716S
-
-
- HY-B0418A
-
-
- HY-100113
-
-
- HY-18776
-
-
- HY-130118
-
|
MRGPRX1 agonist 1
|
Others
|
Neurological Disease
|
|
MRGPRX1 agonist 1 is a highly potent agonist of MRGPRX1 (Mas-related G-protein-coupled receptor X1), with an EC50 of 50 nM, and is inactive on MRGPRC11. Analgesic effect.
|
-
- HY-A0008
-
-
- HY-G0021
-
|
N-Desmethylclozapine
Norclozapine; Desmethylclozapine; Normethylclozapine
|
mAChR
Opioid Receptor
Drug Metabolite
Virus Protease
|
Infection
|
|
N-Desmethylclozapine is a major active metabolite of the atypical antipsychotic drug Clozapine. N-Desmethylclozapine is a potent, allosteric and partial M1 receptors agonist (EC50=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine is also a δ-opioid agonist.
|
-
- HY-10559
-
|
Nelotanserin
APD125
|
5-HT Receptor
|
Cancer
Neurological Disease
|
|
Nelotanserin is a potent 5-HT2A inverse agonist, a moderately potent 5-HT2C partial inverse agonist and a weak 5-HT2B inverse agonist, with IC50s of 1.7, 79, 791 nM in IP accumulation assays, respectively.
|
-
- HY-100532
-
-
- HY-P0108
-
-
- HY-14803
-
-
- HY-10838
-
-
- HY-B2215
-
-
- HY-B0489
-
-
- HY-14917
-
-
- HY-19998
-
-
- HY-16722
-
-
- HY-13720A
-
-
- HY-17633
-
-
- HY-50108
-
-
- HY-U00230
-
-
- HY-N2309
-
-
- HY-33353
-
-
- HY-107480
-
-
- HY-14799
-
-
- HY-14864A
-
-
- HY-P0236
-
-
- HY-B0380A
-
-
- HY-B0380
-
-
- HY-14864
-
-
- HY-U00293
-
-
- HY-101585
-
-
- HY-14304A
-
-
- HY-14304
-
-
- HY-14340
-
|
WAY-181187
SAX-187
|
5-HT Receptor
|
Neurological Disease
|
|
WAY-181187 (SAX-187) is a potent and selective full 5-HT6 receptor agonist with a Ki of 2.2 nM and an EC50 of 6.6 nM. WAY181187 mediates 5-HT6 receptor-dependent signal pathways, such as cAMP, Fyn and ERK1/2 kinase, as specific agonist.
|
-
- HY-13201
-
-
- HY-19961
-
|
KIN1408
|
HCV
|
Infection
|
|
KIN1408 is an antiviral small molecule compound, as agonists of the RLR pathway.
|
-
- HY-13736A
-
-
- HY-P1337
-
-
- HY-16718
-
-
- HY-B0452
-
-
- HY-P0059
-
|
Teriparatide
Human parathyroid hormone-(1-34); PTH 1-34; hPTH (1-34)
|
Others
|
Cancer
|
|
Teriparatide is a PHT agonist, with an IC50 of 2 nM in HEK293 cells.
|
-
- HY-P1470
-
-
- HY-P1336
-
-
- HY-15451
-
-
- HY-103173
-
-
- HY-11076
-
-
- HY-P1532
-
-
- HY-W015326
-
-
- HY-50844
-
-
- HY-13201A
-
-
- HY-P1480
-
-
- HY-B0475
-
-
- HY-P1578
-
-
- HY-108449
-
-
- HY-16748
-
-
- HY-U00038
-
-
- HY-B0648
-
-
- HY-12451
-
-
- HY-128922
-
-
- HY-14773S
-
-
- HY-N0808
-
-
- HY-108472
-
-
- HY-109527
-
-
- HY-41076
-
-
- HY-P1198
-
-
- HY-17366A
-
|
Clozapine N-oxide dihydrochloride
|
mAChR
Dopamine Receptor
Drug Metabolite
|
Neurological Disease
|
|
Clozapine N-oxide dihydrochloride is a major metabolite of Clozapine and a human muscarinic designer receptors (DREADDs) agonist. Clozapine N-oxide dihydrochloride specifically activates the DREADD receptor hM3Dq. Clozapine N-oxide dihydrochloride can cross the blood-brain barrier. Clozapine is a potent dopamine antagonist and also a potent and selective muscarinic M4 receptor (EC50=11 nM) agonist.
|
-
- HY-17366
-
|
Clozapine N-oxide
|
mAChR
Dopamine Receptor
Drug Metabolite
|
Neurological Disease
|
|
Clozapine N-oxide is a major metabolite of Clozapine and a human muscarinic designer receptors (DREADDs) agonist. Clozapine N-oxide specifically activates the DREADD receptor hM3Dq. Clozapine N-oxide can cross the blood-brain barrier. Clozapine is a potent dopamine antagonist and also a potent and selective muscarinic M4 receptor (EC50=11 nM) agonist.
|
-
- HY-16713A
-
-
- HY-U00216
-
-
- HY-P1087
-
-
- HY-14299
-
-
- HY-15564
-
-
- HY-19661
-
-
- HY-113035
-
-
- HY-101038A
-
-
- HY-P0080
-
-
- HY-14299A
-
-
- HY-16713
-
-
- HY-B0189
-
-
- HY-B0188
-
-
- HY-100273
-
-
- HY-12848B
-
|
SAG hydrochloride
|
Smo
|
Cancer
|
|
SAG (hydrochloride) is a potent Smo receptor agonist, and activates the Hedgehog signaling pathway, with a Kd of 59 nM.
|
-
- HY-111132
-
-
- HY-B0570
-
-
- HY-13673A
-
-
- HY-B0180A
-
-
- HY-13673
-
-
- HY-111068
-
-
- HY-17622
-
-
- HY-P1578A
-
-
- HY-U00226
-
-
- HY-B0180B
-
-
- HY-21098A
-
-
- HY-19250
-
-
- HY-N2371
-
-
- HY-13571A
-
-
- HY-19468
-
-
- HY-P1337A
-
-
- HY-101973
-
-
- HY-B0374A
-
-
- HY-P1481
-
-
- HY-101033
-
|
GPR35 agonist 1
|
Others
|
Cancer
Endocrinology
|
|
GPR35 agonist 1 (compound 50) is a potent and specific G protein-coupled receptor-35 (GPR35)/CXCR8 agonist with an EC50 of 5.8 nM, displays good druggability.
|
-
- HY-N2411
-
-
- HY-128573
-
-
- HY-19320
-
-
- HY-108258A
-
|
PSN 375963 hydrochloride
|
GPR119
|
Endocrinology
|
|
PSN 375963 hydrochloride is a potent GPR119 agonist, with EC50s of 8.4 and 7.9 μM for human and mouse GPR119, respectively. PSN 375963 hydrochloride shows similar potency to the endogenous agonist oleoylethanolamide (OEA).
|
-
- HY-P0080A
-
-
- HY-114146
-
-
- HY-101864
-
-
- HY-100124
-
-
- HY-P1477
-
-
- HY-12848
-
|
SAG
|
Smo
|
Cancer
|
|
SAG is a potent Smo receptor agonist which activates the Hedgehog signaling pathway with a Kd of 59 nM.
|
-
- HY-B0091A
-
-
- HY-12749A
-
-
- HY-109111
-
-
- HY-15108
-
-
- HY-U00400
-
-
- HY-17355A
-
-
- HY-101274
-
-
- HY-11077
-
-
- HY-B0189A
-
-
- HY-107319
-
-
- HY-12749
-
-
- HY-19838
-
-
- HY-113035A
-
-
- HY-14734
-
-
- HY-B0406A
-
|
Bethanechol chloride
Carbamyl-β-methylcholine chloride
|
mAChR
|
Metabolic Disease
|
|
Bethanechol Chloride (Carbamyl-β-methylcholine chloride) is a selective muscarinic receptor agonist without any effect on nicotinic receptors.
|
-
- HY-12664
-
-
- HY-B0091
-
-
- HY-14734B
-
-
- HY-101271
-
-
- HY-14734A
-
-
- HY-14652
-
-
- HY-P1515
-
-
- HY-111454
-
-
- HY-79593
-
-
- HY-B0409A
-
-
- HY-101582
-
-
- HY-16086
-
-
- HY-11062
-
-
- HY-12499
-
-
- HY-U00233
-
-
- HY-P1198A
-
-
- HY-B0436
-
-
- HY-14958A
-
-
- HY-14958
-
-
- HY-135572
-
-
- HY-P1192
-
-
- HY-P1123
-
|
MEDICA16
|
ATP Citrate Lyase
GPR40
GPR120
|
Metabolic Disease
|
|
MEDICA16, an ATP-citrate lyase inhibitor, significantly reduces intracellular TG content in gastrocnemius muscle, and this reduction is accompanied by an increase in insulin sensitivity. MEDICA16 is a selective agonist for GPR40 as well as selective partial agonists for GPR120.
|
-
- HY-14773
-
-
- HY-P0079
-
-
- HY-114116
-
-
- HY-12066
-
-
- HY-100676
-
-
- HY-W014666
-
-
- HY-101639A
-
-
- HY-102075A
-
-
- HY-100336
-
-
- HY-10475
-
|
AM580
CD336; NSC608001; Ro 40-6055
|
RAR/RXR
Autophagy
|
Cancer
|
|
AM580 is a selective RARα agonist with IC50 and EC50 of 8 nM and 0.36 nM, respectively.
|
-
- HY-B0180
-
-
- HY-101384A
-
-
- HY-100140
-
-
- HY-41700
-
-
- HY-B1403
-
-
- HY-101299
-
-
- HY-16972
-
|
SR9243
|
LXR
|
Cancer
|
|
SR9243 is a liver-X-receptor (LXR) inverse agonist that induces LXR-corepressor interaction.
|
-
- HY-N6629
-
-
- HY-B0664S
-
|
Ciprofibrate D6
|
PPAR
|
Cancer
|
|
Ciprofibrate D6 is deuterium labeled Ciprofibrate, which is a peroxisome proliferator-activated receptor agonist.
|
-
- HY-104026
-
-
- HY-100291
-
-
- HY-50935
-
-
- HY-101987
-
-
- HY-P1515A
-
-
- HY-13101
-
-
- HY-19883
-
-
- HY-10435
-
-
- HY-A0083
-
|
Methacholine chloride
Acetyl-β-methylcholine chloride
|
mAChR
|
Others
|
|
Methacholine chloride is a synthetic choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system.
|
-
- HY-N0178
-
-
- HY-P1467
-
-
- HY-P0088
-
-
- HY-100166
-
-
- HY-13421
-
-
- HY-101639
-
-
- HY-103704
-
-
- HY-16737
-
-
- HY-107216
-
-
- HY-P1477A
-
-
- HY-10002
-
-
- HY-122872
-
|
MKK7-COV-9
|
p38 MAPK
|
Cancer
|
|
MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC50 of 4.98 μM.
|
-
- HY-N0166
-
-
- HY-P1405
-
-
- HY-P1467A
-
-
- HY-B0188A
-
-
- HY-100140A
-
-
- HY-14785
-
-
- HY-P1145
-
-
- HY-19334
-
-
- HY-14785A
-
-
- HY-15306
-
-
- HY-109197
-
-
- HY-N3216
-
-
- HY-16465
-
-
- HY-12721
-
-
- HY-P1331
-
-
- HY-109032
-
-
- HY-U00206
-
-
- HY-111271
-
-
- HY-18939
-
-
- HY-B0716
-
-
- HY-14870
-
-
- HY-14648A
-
-
- HY-108003
-
-
- HY-A0168
-
-
- HY-P0226
-
-
- HY-19919
-
|
BMS-779788
EXEL04286652; XL-652; BMS-788
|
LXR
|
Metabolic Disease
|
|
BMS-779788 is a LXR partial agonist with IC50 values of 68 nM for LXRα and 14 nM for LXRβ.
|
-
- HY-10922A
-
-
- HY-P2321
-
-
- HY-108414
-
-
- HY-A0040
-
-
- HY-P2273
-
|
Calcitonin (human)
|
CGRP Receptor
|
|
|
Calcitonin human is an endogenous calcitonin receptor agonist.Calcitonin human lowers systemic blood calcium levels and inhibits bone resorption.
|
-
- HY-19942A
-
-
- HY-19308
-
-
- HY-13788B
-
-
- HY-15388
-
-
- HY-B0374
-
-
- HY-B0769
-
-
- HY-17551
-
-
- HY-10922
-
-
- HY-N0586
-
-
- HY-12023
-
|
Andarine
GTx-007; S-4
|
Androgen Receptor
|
Cancer
|
|
Andarine (S-4) is an investigational selective androgen receptor modulator (SARM) and an active partial agonist.
|
-
- HY-120879
-
|
PF2562
|
Dopamine Receptor
|
Neurological Disease
|
|
PF2562 (Example 6), a dopamine D1 ligand, ascts as a dopamine D1 agonist or partial agonist. PF2562 binds to human D1 receptor with a Ki of 113 nM. PF2562 exhibits activity against human D1 cAMP with an EC50 of 568 nM in HTRF assay.
|
-
- HY-14229
-
-
- HY-101630
-
|
Deramciclane
EGIS-3886
|
5-HT Receptor
|
Neurological Disease
|
|
Deramciclane has a high affinity for 5-HT2A and 5-HT2C receptors; it acts as an antagonist at both receptor subtypes and has inverse agonist properties at the 5-HT2C receptors without direct stimulatory agonist.
|
-
- HY-10233
-
|
Gaboxadol hydrochloride
Lu 02-030 hydrochloride; THIP hydrochloride
|
GABA Receptor
|
Neurological Disease
|
|
Gaboxadol hydrochloride (Lu 02-030 hydrochloride; THIP hydrochloride) is a potent agonist of the GABAA receptor and an antagonist of GABAC receptors (IC50=25 μM). Gaboxadol hydrochloride displays
a partial agonist efficacy on subunit α1β2γ2 with an ED50 value of 143 µM, a full agonist efficacy at α5 subunit (ED50=28-129 µM) and a superagonist efficacy at α4β3δ (ED50=6 µM). Gaboxadol hydrochloride is a non-opioid analgesic and has hypnotic activities.
|
-
- HY-133011
-
|
nAChR agonist 1
|
nAChR
|
Neurological Disease
|
|
nAChR agonist 1 is a potent, brain-permeable, and orally efficacious positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR). nAChR agonist 1 has the EC50 of 0.32 µM in a Ca 2+ mobilization assay (PNU-282987-induced, FLIPR based) in human IMR-32 neuroblastoma cells that endogenously express α7 nAChR. nAChR agonist 1 can be develpoped for the treatment of Alzheimer’s disease.
|
-
- HY-15430A
-
-
- HY-W014325
-
-
- HY-17457
-
-
- HY-P0297
-
-
- HY-70037
-
-
- HY-112322
-
-
- HY-19945
-
|
DAA-1106
|
GABA Receptor
|
Neurological Disease
|
|
DAA1106 is a potent and selective ligand for peripheral benzodiazepine receptor (PBR), as a potent and selective agonist at the peripheral benzodiazepine receptor.
|
-
- HY-12111
-
-
- HY-107542
-
-
- HY-B0194A
-
-
- HY-B0566
-
-
- HY-100673
-
-
- HY-101420
-
-
- HY-P1145A
-
-
- HY-101649
-
-
- HY-112627
-
-
- HY-14899
-
-
- HY-114025
-
-
- HY-12199
-
-
- HY-15430
-
-
- HY-76772A
-
-
- HY-15885
-
-
- HY-107418
-
-
- HY-B0726
-
-
- HY-12199B
-
-
- HY-15291
-
-
- HY-14171
-
|
Bexarotene
LGD1069
|
RAR/RXR
Autophagy
|
Cancer
|
|
Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma.
|
-
- HY-B0194
-
-
- HY-100347A
-
-
- HY-P1339
-
-
- HY-10480
-
-
- HY-P1545
-
-
- HY-10435A
-
-
- HY-15677
-
-
- HY-P2279
-
-
- HY-101822
-
-
- HY-U00014
-
|
AVE-8134
|
PPAR
|
Metabolic Disease
|
|
AVE-8134 is a potent PPARα agonist, with EC50 values of 100 and 3000 nM for human and rodent PPARα receptor, respectively.
|
-
- HY-14149
-
-
- HY-101492
-
-
- HY-P1349
-
-
- HY-P0226A
-
-
- HY-19434
-
|
trans-ACPD
Trans-(±)-ACP
|
mGluR
|
Metabolic Disease
|
|
trans-ACPD, a metabotropic receptor agonist, produces calcium mobilization and an inward current in cultured cerebellar Purkinje neurons.
|
-
- HY-13665
-
|
Leuprolide Acetate
Leuprorelin acetate
|
GNRH Receptor
|
Endocrinology
Cancer
|
|
Leuprolide acetate (Leuprorelin acetate) is a potent gonadotropin-releasing hormone receptor agonist used for the treatment of prostate cancer, endometriosis, uterine fibroids.
|
-
- HY-P1334
-
-
- HY-131103
-
-
- HY-P2321A
-
-
- HY-103107
-
-
- HY-76772B
-
-
- HY-P1577
-
-
- HY-B0468
-
-
- HY-16998
-
|
SR2211
|
ROR
|
Inflammation/Immunology
|
|
SR2211 is a potent, selective synthetic RORγ modulator and functions as an inverse agonist, with a Ki of 105 nM and an IC50 of ~320 nM.
|
-
- HY-B0010
-
-
- HY-100775
-
|
Setogepram sodium salt
PBI-4050 sodium salt
|
GPR40
GPR84
|
Metabolic Disease
Inflammation/Immunology
|
|
Setogepram sodium salt (PBI-4050 sodium salt) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84. Setogepram sodium salt decreases renal, liver and pancreatic fibrosis. Setogepram sodium salt exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions.
|
-
- HY-14417B
-
|
VU0155041 sodium
|
mGluR
|
Neurological Disease
|
|
VU0155041 sodium is a potent, selective and mixed allosteric agonist/positive allosteric modulator (PAM) of mGluR4, with EC50s of 798 nM and 693 nM for human and rat mGluR4, respectively. VU0155041 sodium is a partial agonist of mGluR4 that activates the receptor by interacting with a site that is distinct from the glutamate binding site.
|
-
- HY-115400
-
|
1V209
TLR7 agonist T7
|
Toll-like Receptor (TLR)
|
Cancer
|
|
1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. 1V209 can be conjugated with various polysaccharides to improve its water solubility, and enhance its efficacy, and maintain low toxicity.
|
-
- HY-129656
-
-
- HY-B0545
-
-
- HY-14546
-
-
- HY-14261
-
-
- HY-107675
-
-
- HY-106094
-
-
- HY-B0084
-
-
- HY-P1533
-
-
- HY-17034B
-
-
- HY-14153A
-
-
- HY-P1031
-
-
- HY-B0735
-
-
- HY-12199A
-
-
- HY-18100A
-
-
- HY-B0447A
-
-
- HY-B1006
-
-
- HY-17034A
-
-
- HY-13044
-
-
- HY-103187
-
-
- HY-111786
-
-
- HY-101331
-
-
- HY-70037A
-
-
- HY-P1588
-
-
- HY-102016
-
-
- HY-12584
-
-
- HY-108526
-
-
- HY-101540
-
-
- HY-B0735A
-
-
- HY-10912
-
|
Fexaramine
|
FXR
Autophagy
|
Others
|
|
Fexaramine is a small molecule farnesoid X receptor (FXR) agonist with 100-fold increased affinity relative to natural compounds.
|
-
- HY-P1339A
-
-
- HY-B0206
-
-
- HY-P1261
-
-
- HY-B0577
-
-
- HY-14933
-
-
- HY-A0014
-
-
- HY-103098
-
-
- HY-101386
-
-
- HY-15566
-
|
APD597
JNJ-38431055
|
GPR119
|
Metabolic Disease
|
|
APD597 is a GPR119 agonist intended for the treatment of type 2 diabetes, with EC50 of 46 nM for hGPR119.
|
-
- HY-100856
-
-
- HY-P0210
-
-
- HY-B1832
-
-
- HY-P1545A
-
-
- HY-18723
-
-
- HY-12216
-
-
- HY-101609
-
-
- HY-16162
-
|
D-3263
|
TRP Channel
|
Cancer
|
|
D-3263 is an agonist of transient receptor potential melastatin member 8 (TRPM8) with potential antineoplastic activity.
|
-
- HY-P1262
-
-
- HY-100256
-
-
- HY-135905
-
-
- HY-B1752A
-
-
- HY-100490
-
|
Rilmenidine
|
Imidazoline Receptor
Adrenergic Receptor
Apoptosis
Autophagy
|
Cardiovascular Disease
|
|
Rilmenidine, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine is an alpha 2-adrenoceptor agonist. Rilmenidine induces autophagy. Rilmenidine modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells.
|
-
- HY-A0007
-
-
- HY-P1309
-
-
- HY-133552
-
|
RORγt Inverse agonist 10
|
ROR
|
Inflammation/Immunology
|
|
RORγt Inverse agonist 10 is a potent and orally bioavailable RORγt (retinoic acid receptor-related orphan nuclear receptor gamma t) inverse agonist, with an IC50 of 51 nM. RORγt is a major transcription factor of genes related to psoriasis pathogenesis such as IL-17A, IL-22, and IL-23R
|
-
- HY-13457
-
|
TCN 201
|
iGluR
|
Neurological Disease
|
|
TCN 201 is a potent, selective and non-competitive antagonist of GluN1/GluN2A NMDAR. TCN 201 antagonism is dependent on the GluN1-agonist concentration. TCN 201 allows pharmacological identification of native GluN2A-containing NMDAR populations.
|
-
- HY-N0175
-
|
Cytisinicline
Cytisine; Sophorine; Baptitoxine
|
nAChR
|
Metabolic Disease
|
|
Cytisinicline (Cytisine) is an alkaloid that occurs naturally in several plant genera, such as Laburnum and Cytisus. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs, and partial to full agonist at β4 containing receptors and α7 receptors. Has been used medically to help with smoking cessation.
|
-
- HY-19511
-
|
GSK2018682
|
LPL Receptor
|
Inflammation/Immunology
|
|
GSK2018682 is an agonist for S1P1 and S1P5 receptor with pEC50s of 7.7 and 7.2, respectively, and has no agonist activity towards human S1P2, S1P3, or S1P4. GSK2018682 is used in the research of multiple sclerosis.
|
-
- HY-136586
-
-
- HY-103225
-
-
- HY-B1583
-
-
- HY-P1164
-
-
- HY-16988A
-
-
- HY-B0459
-
-
- HY-19365
-
-
- HY-114165
-
-
- HY-100328
-
-
- HY-14601
-
-
- HY-100728
-
-
- HY-15565
-
-
- HY-16916
-
-
- HY-17030
-
-
- HY-P0210B
-
-
- HY-B0197A
-
-
- HY-P1262A
-
-
- HY-13591
-
-
- HY-13715
-
-
- HY-P1261A
-
-
- HY-13788
-
-
- HY-12520A
-
-
- HY-16162A
-
-
- HY-107384
-
-
- HY-16989
-
|
SR9009
|
Autophagy
|
Cancer
|
|
SR9009 is a REV-ERBα/β agonist with IC50s of 670 nM and 800 nM for REV-ERBα and REV-ERBβ, respectively.
|
-
- HY-109096
-
-
- HY-14302
-
-
- HY-16685
-
-
- HY-130115
-
|
IACS-8803
|
STING
|
Cancer
|
|
IACS-8803 is a highly potent cyclic dinucleotide STING agonist with robust systemic antitumor efficacy.
|
-
- HY-15536A
-
-
- HY-15601
-
-
- HY-P0244
-
-
- HY-15778
-
-
- HY-10487
-
-
- HY-16988
-
|
SR9011
|
Autophagy
|
Cancer
|
|
SR9011 is a REV-ERBα/β agonist with IC50s of 790 nM and 560 nM for REV-ERBα and REV-ERBβ, respectively.
|
-
- HY-101273
-
-
- HY-P0098
-
-
- HY-P0090
-
|
Calcitonin (salmon)
Salmon calcitonin
|
CGRP Receptor
|
Cancer
|
|
Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.
|
-
- HY-B0197
-
-
- HY-112152
-
-
- HY-14426
-
-
- HY-B0659
-
-
- HY-111498
-
-
- HY-B0225
-
-
- HY-P1030
-
-
- HY-14817
-
-
- HY-B0410
-
-
- HY-15243
-
-
- HY-13715A
-
-
- HY-16465A
-
-
- HY-B0197AS
-
-
- HY-B0354A
-
-
- HY-B0802
-
-
- HY-W015878
-
-
- HY-15306A
-
-
- HY-13788C
-
-
- HY-19774
-
-
- HY-14413
-
|
SR3335
ML 176
|
ROR
|
Metabolic Disease
|
|
SR3335 (ML 176) is a selective RORα inverse agonist that directly binds to RORα with a Ki of 220 nM.
|
-
- HY-19775
-
-
- HY-75502
-
-
- HY-101300
-
-
- HY-P1102
-
|
TC14012
|
CXCR
HIV
|
Cancer
Infection
|
|
TC14012, a serum-stable derivative of T140, is a selective and peptidomimetic inverse CXCR4 agonist with an IC50 of 19.3 nM. TC14012 is a potent CXCR7 agonist an EC50 of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 has anti-HIV activity and anti-cancer activity.
|
-
- HY-100775A
-
|
Setogepram
PBI-4050
|
GPR40
GPR84
|
Metabolic Disease
Inflammation/Immunology
|
|
Setogepram (PBI-4050) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84. Setogepram (PBI-4050) decreases renal, liver and pancreatic fibrosis. Setogepram (PBI-4050) exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions.
|
-
- HY-136429
-
|
Ethylhydrocupreine
Optochin
|
Bacterial
Parasite
|
Infection
|
|
Ethylhydrocupreine (Optochin) is a quinine derivate with antimicrobial activity against S. pneumoniae. Ethylhydrocupreine also possesses antimalarial activity against Plasmodium falciparum, with an IC50 of 25.75 nM. Ethylhydrocupreine is a Gallus gallus taste 2 receptors (ggTas2r1, ggTas2r2 and ggTas2r7) agonist.
|
-
- HY-136429A
-
|
Ethylhydrocupreine hydrochloride
Optochin hydrochloride
|
Bacterial
Parasite
|
Infection
|
|
Ethylhydrocupreine hydrochloride (Optochin hydrochloride) is a quinine derivate with antimicrobial activity against S. pneumoniae. Ethylhydrocupreine hydrochloride also possesses antimalarial activity against Plasmodium falciparum, with an IC50 of 25.75 nM. Ethylhydrocupreine hydrochloride is a Gallus gallus taste 2 receptors (ggTas2r1, ggTas2r2 and ggTas2r7) agonist.
|
-
- HY-126047B
-
|
(R)-(+)-Anatabine
|
NF-κB
Amyloid-β
nAChR
|
Inflammation/Immunology
Neurological Disease
|
|
(R)-(+)-Anatabine is an less active R-enantiomer of Anatabine. Anatabine is a potent α4β2 nAChR agonist. Anatabine inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of amyloid precursor protein (APP). Anatabine has anti-inflammatory effects and has the potential for neurodegenerative disorders treatment.
|
-
- HY-B0979
-
|
Lobeline hydrochloride
α-Lobeline hydrochloride; L-Lobeline hydrochloride
|
nAChR
|
Neurological Disease
|
|
Lobeline hydrochloride, a nicotinic receptor agonist, acting as a potent antagonist at both α3β2 and α4β2 neuronal nicotinic receptor subtypes.
|
-
- HY-A0007S
-
-
- HY-130116
-
|
IACS-8779
|
STING
|
Cancer
|
|
IACS-8779 is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy.
|
-
- HY-15401
-
-
- HY-16728
-
|
Rapastinel
GLYX-13
|
iGluR
|
Neurological Disease
|
|
Rapastinel (GLYX-13) is an N-methyl-D-aspartate receptor (NMDAR) modulator that has characteristics of a glycine site partial agonist.
|
-
- HY-101037
-
|
Sarcosine
N-Methylglycine; Sarcosin
|
Endogenous Metabolite
GlyT
|
Cancer
|
|
Sarcosine is a glycine transporter type 1 (GlyT) inhibitor and an N-methyl-D-aspartate (NMDA) receptor co-agonist at the glycine binding site.
|
-
- HY-P1164A
-
-
- HY-P0177
-
-
- HY-14351
-
-
- HY-P0244A
-
-
- HY-B0100
-
-
- HY-101950
-
-
- HY-13604
-
-
- HY-P1127
-
-
- HY-10629
-
-
- HY-B0225B
-
-
- HY-50919
-
|
Paricalcitol
|
VD/VDR
|
Metabolic Disease
|
|
Paricalcitol is a vitamin D receptor agonist, used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure.
|
-
- HY-14564A
-
-
- HY-B0225A
-
-
- HY-13510
-
-
- HY-N0382
-
|
Galangin
Norizalpinin; 3,5,7-Trihydroxyflavone
|
Cytochrome P450
Autophagy
|
Cancer
|
|
Galangin (Norizalpinin) is an agonist/antagonist of the arylhydrocarbon receptor. Galangin (Norizalpinin) also shows inhibition of CYP1A1 activity.
|
-
- HY-17573
-
|
Carbetocin
|
Oxytocin Receptor
|
Endocrinology
|
|
Carbetocin (Lonactene; Duratocin) is an obstetric drug used to control postpartum hemorrhage and bleeding after giving birth; an agonist at peripheral oxytocin receptors.
|
-
- HY-13788A
-
-
- HY-103410
-
-
- HY-101442
-
|
SR9238
|
LXR
|
Metabolic Disease
|
|
SR9238 is a synthetic liver X receptor (LXR) inverse agonist with IC50s of 214 nM and 43 nM for LXRα and LXRβ, respectively.
|
-
- HY-B0383A
-
-
- HY-14953
-
|
Imepitoin
AWD 131-138
|
GABA Receptor
|
Neurological Disease
|
|
Imepitoin (AWD 131-138) is a new low-affinity partial benzodiazepine receptor agonist with potent anticonvulsant and anxiolytic properties in rodent models.
|
-
- HY-101419
-
-
- HY-U00371
-
-
- HY-101640
-
-
- HY-14831
-
|
Arhalofenate
MBX 102; JNJ 39659100
|
PPAR
|
Metabolic Disease
|
|
Arhalofenate (MBX 102) is a selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ, used for the treatment of type 2 diabetes.
|
-
- HY-19863
-
-
- HY-19317
-
-
- HY-N2311
-
|
Ibotenic acid
(RS)-Ibotenic acid; DL-Ibotenic acid
|
iGluR
|
Neurological Disease
|
|
Ibotenic acid has agonist activity at both the N-methyl-D-aspartate (NMDA) and trans-ACPD or metabolotropic quisqualate (Qm) receptor sites.
|
-
- HY-50911
-
-
- HY-B0447
-
-
- HY-P1481A
-
-
- HY-133528
-
-
- HY-P1102A
-
|
TC14012 TFA
|
CXCR
HIV
|
Cancer
Infection
|
|
TC14012 TFA, a serum-stable derivative of T140, is a selective and peptidomimetic inverse CXCR4 agonist with an IC50 of 19.3 nM. TC14012 TFA is a potent CXCR7 agonist an EC50 of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 TFA has anti-HIV activity and anti-cancer activity.
|
-
- HY-18978
-
-
- HY-100171
-
-
- HY-N0783
-
-
- HY-P0298
-
-
- HY-14782
-
-
- HY-101586
-
-
- HY-102075B
-
|
TMP780
|
ROR
|
Inflammation/Immunology
|
|
TMP780 is an inverse agonist of RORγt with an IC50 of 13 nM. RORγt is a tractable drug target for the treatment of cutaneous inflammatory disorders.
|
-
- HY-17501
-
|
Bambuterol
(±)-Bambuterol; KWD-2183
|
Adrenergic Receptor
|
Endocrinology
|
|
Bambuterol ((±)-Bambuterol; KWD-2183) is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline.
|
-
- HY-111775
-
-
- HY-101238
-
-
- HY-16688
-
-
- HY-B0154
-
-
- HY-17355B
-
-
- HY-19995
-
-
- HY-P1012
-
-
- HY-128604
-
|
XY101
|
ROR
|
Cancer
|
|
XY101 is a potent, selective, metabolically stable and orally available RORγ inverse agonist with an IC50 of 30 nM and a Kd of 380 nM.
|
-
- HY-109044
-
-
- HY-P0298A
-
-
- HY-B1473
-
-
- HY-14342
-
-
- HY-B0659A
-
-
- HY-17501A
-
|
Bambuterol hydrochloride
(±)-Bambuterol hydrochloride; KWD-2183 hydrochloride
|
Adrenergic Receptor
|
Endocrinology
|
|
Bambuterol hydrochloride ((±)-Bambuterol hydrochloride; KWD-2183 hydrochloride) is a long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma; it also is a prodrug of terbutaline.
|
-
- HY-109104
-
-
- HY-111149
-
-
- HY-101777
-
-
- HY-14792
-
|
Inolitazone
Efatutazone; CS-7017; RS5444
|
PPAR
|
Cancer
|
|
Inolitazone a novel high-affinity PPARγ agonist that is dependent upon PPARγ for its biological activity with IC50 of 0.8 nM for growth inhibition.
|
-
- HY-13338S
-
-
- HY-10448
-
|
Capsaicin
(E)-Capsaicin
|
TRP Channel
Autophagy
|
Cancer
|
|
Capsaicin ((E)-Capsaicin) is a mixture of Capsaicin and Dihydrocapsaicin. Capsaici is a TRPV1 agonist with an EC50 of 0.29 μM in HEK293 cells.
|
-
- HY-10021
-
-
- HY-16684
-
|
AGN 195183
|
RAR/RXR
Autophagy
|
Cancer
|
|
AGN 195183 is a potent and selective agonist of RARα(Kd=3 nM) with improved binding selectivity relative to AGN 193836; no activity on RARβ/γ.
|
-
- HY-101787
-
-
- HY-101192
-
-
- HY-B0383
-
-
- HY-P0014
-
-
- HY-18687
-
-
- HY-14562
-
|
TBPB
|
mAChR
|
Neurological Disease
|
|
TBPB is an allosteric M1 mAChR agonist(EC50=289 nM) that regulates amyloid processing and produces antipsychotic-like activity in rats.
|
-
- HY-14167
-
-
- HY-P1309A
-
-
- HY-110160
-
|
Pozanicline dihydrochloride
ABT-089 dihydrochloride
|
nAChR
|
Neurological Disease
|
|
Pozanicline dihydrochloride (ABT-089 dihydrochloride) is an orally bioavailable nicotinic acetylcholine receptor (nAChR) agonist with a Ki of 16.7 nM for binding to [ 3H]cytisine sites. Pozanicline is an α4β2-selective nAChR agonist, which binds to rat brain α4β2 nAChR with a Ki of 17 nM while binding to α7 nAChR is insignificant.
|
-
- HY-111406
-
|
Omidenepag isopropyl
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
Omidenepag isopropyl is a selective EP2 receptor agonist. Omidenepag isopropyl is converted to the active product Omidenepag during corneal penetration, and Omidenepag is a highly selective EP2 receptor agonist. Omidenepag isopropyl shows only weak affinity for EP1, EP2, and FP receptors. Omidenepag isopropyl is under development for the treatment of glaucoma as an intraocular pressure (IOP)-lowering drug.
|
-
- HY-A0182A
-
-
- HY-111269
-
-
- HY-B0031S
-
-
- HY-14792B
-
|
Inolitazone dihydrochloride
Efatutazone dihydrochloride; CS-7017 dihydrochloride; RS5444 dihydrochloride
|
PPAR
|
Cancer
|
|
Inolitazone dihydrochloride (Efatutazone dihydrochloride) is a novel high-affinity PPARγ agonist that is dependent upon PPARγ for its biological activity with IC50 of 0.8 nM for growth inhibition.
|
-
- HY-P1869
-
-
- HY-15848
-
-
- HY-N0377
-
-
- HY-13773
-
-
- HY-13443
-
-
- HY-B1893
-
-
- HY-100443B
-
-
- HY-P1012A
-
-
- HY-15443
-
-
- HY-B0100A
-
-
- HY-B1347
-
-
- HY-19134
-
-
- HY-B0606
-
-
- HY-14557
-
-
- HY-B0418AS
-
-
- HY-17584
-
|
Linaclotide
|
Guanylate Cyclase
|
Others
|
|
Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.
|
-
- HY-19946
-
-
- HY-110164
-
-
- HY-111200
-
-
- HY-100013C
-
-
- HY-14898
-
-
- HY-P1533A
-
-
- HY-16728B
-
|
Rapastinel Trifluoroacetate
GLYX-13 Trifluoroacetate
|
iGluR
|
Neurological Disease
|
|
Rapastinel Trifluoroacetate (GLYX-13 Trifluoroacetate) is an NMDA receptor modulator with glycine-site partial agonist properties. Rapastinel Trifluoroacetate has the potential for major depressive disorder treatment.
|
-
- HY-11035
-
|
WAY-262611
|
β-catenin
|
Cancer
|
|
WAY-262611 is a wingless β-Catenin agonist that increases bone formation rate with an EC50 of 0.63 μM in TCF-Luciferase assay.
|
-
- HY-B0823
-
|
Acetamiprid
|
nAChR
|
Neurological Disease
|
|
Acetamiprid is a neonicotinoid insecticide used worldwide. Acetamiprid is a nicotinic acetylcholine receptor (nAChR) agonist, and is shown to be associated with neuromuscular and reproductive disorders.
|
-
- HY-14887
-
-
- HY-A0182
-
-
- HY-13443A
-
-
- HY-U00215
-
|
Ro 41-3290
|
GABA Receptor
|
Neurological Disease
|
|
Ro 41-3290 is the desethylated derivative of Ro 41-3696, which is a nonbenzodiazepine partial agonist at the benzodiazepine receptor. Ro 41-3290 is an investigational hypnotic.
|
-
- HY-14218
-
-
- HY-B0121
-
-
- HY-16504
-
-
- HY-N0322
-
|
Cholesterol
|
Estrogen Receptor/ERR
Endogenous Metabolite
|
Metabolic Disease
|
|
Cholesterol is the major sterol in mammals and is makes up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist.
|
-
- HY-13291
-
-
- HY-P1333
-
|
Dynorphin A
|
Opioid Receptor
|
Neurological Disease
|
|
Dynorphin A, an endogenous opioid peptide, is a highy potent kappa opioid receptor (KOR) activator. Dynorphin A also serve as an agonist for other opioid receptors, such as mu (MOR) and delta (DOR).
|
-
- HY-114269
-
-
- HY-111098
-
-
- HY-14728
-
-
- HY-119943
-
-
- HY-A0190
-
-
- HY-B0459A
-
-
- HY-N6709
-
|
Zeranol
α-Zearalanol
|
Estrogen Receptor/ERR
|
Endocrinology
|
|
Zeranol, a metabolite of the mycoestrogen zearalenone, is an estrogen receptor agonist. Zeranol is used as a growth promoter of livestock due to its strong estrogenic activity.
|
-
- HY-111110
-
-
- HY-124540B
-
-
- HY-19770
-
|
GSK2981278
|
ROR
|
Inflammation/Immunology
|
|
GSK2981278 is a potent and selective RORγ inverse agonist. GSK2981278 inhibits activation of the il17 promoter and interferes RORγ-DNA binding.
|
-
- HY-106266
-
-
- HY-13967
-
|
AMG 837
|
GPR40
|
Metabolic Disease
|
|
AMG 837 is a potent GPR40 agonist(EC50=13 nM) with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents.
|
-
- HY-101929
-
-
- HY-U00183
-
-
- HY-13861
-
-
- HY-13967A
-
|
AMG 837 sodium salt
|
GPR40
|
Metabolic Disease
|
|
AMG 837 sodium salt is a potent GPR40 agonist(EC50=13 nM) with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents.
|
-
- HY-Y0966
-
-
- HY-14557A
-
-
- HY-U00373
-
-
- HY-111492
-
|
DIM-C-pPhOCH3
|
Others
|
Cancer
|
|
DIM-C-pPhOCH3 is a Nur77 agonist. Nerve growth factor-induced Bα (NGFI-Bα, Nur77) is an orphan nuclear receptor.
|
-
- HY-135601
-
-
- HY-103207
-
-
- HY-101869
-
-
- HY-13467
-
-
- HY-108532
-
|
AC-261066
|
RAR/RXR
|
Cancer
|
|
AC-261066 is a potent, orally available and isoform-selective retinoic acid beta2 (RARbeta2) receptor agonist, with a pEC50 of 8.0.
|
-
- HY-15027
-
-
- HY-B1111
-
-
- HY-B1037
-
-
- HY-P1314
-
-
- HY-16751
-
-
- HY-P1170
-
-
- HY-P0119A
-
-
- HY-128113
-
-
- HY-100881
-
-
- HY-12705A
-
-
- HY-P0119
-
-
- HY-20019
-
|
L-165041
|
PPAR
|
Metabolic Disease
|
|
L-165041 is a cell permeable PPARδ agonist, with Kis of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells.
|
-
- HY-17568
-
|
Nonivamide
Pelargonic acid vanillylamide; Nonanoic acid vanillylamide; Pseudocapsaicin
|
TRP Channel
|
Neurological Disease
|
|
Nonivamide is a agonist, which exhibits 4d-EC50 value of 5.1 mg/L in static toxicity tests.
|
-
- HY-P0185
-
-
- HY-114380
-
|
Radioprotectin-1
|
LPL Receptor
|
Others
|
|
Radioprotectin-1 is a potent and specific nonlipid agonist of lysophosphatidic acid receptor 2 (LPA2), with an EC50 value of 25 nM for murine LPA2 subtype.
|
-
- HY-B0106A
-
-
- HY-10627A
-
-
- HY-130012
-
-
- HY-10627
-
|
GW3965
|
LXR
|
Cardiovascular Disease
|
|
GW3965 is a potent, selective liver X receptor (LXR) agonist with EC50s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively.
|
-
- HY-14414
-
|
GSK4112
SR6452
|
Autophagy
|
Metabolic Disease
|
|
GSK4112 is a Rev-erbα agonist with EC50 of 0.4 μM, also is a small molecule chemical probe for the cell biology of the nuclear heme receptor Rev-erbα.
|
-
- HY-14839
-
-
- HY-P0186
-
-
- HY-125824
-
-
- HY-N0169
-
-
- HY-119433
-
|
Asoprisnil
J867
|
Progesterone Receptor
|
Endocrinology
|
|
Asoprisnil (J867), a selective progesterone receptor modulator, exhibits mixed progesterone agonist and antagonist effects on various progesterone targeted tissues in animal and human.
|
-
- HY-118930
-
-
- HY-100155
-
|
4-IBP
|
Sigma Receptor
|
Cancer
|
|
4-IBP is a selective σ1 agonist with a high level of affinity for the σ1 receptor (Ki = 1.7 nM) and a moderate affinity for the σ2 receptor (Ki = 25.2 nM) .
|
-
- HY-100032
-
-
- HY-16642A
-
-
- HY-13967B
-
-
- HY-B1052
-
-
- HY-B1270
-
-
- HY-14823
-
-
- HY-N2253
-
-
- HY-105634A
-
|
Nomegestrol acetate
|
Progesterone Receptor
|
Endocrinology
|
|
Nomegestrol acetate is a potent, highly selective progestogen, which is characterized as a full agonist at the progesterone receptor, with no or minimal binding to other steroid receptors, including the androgen and glucocorticoid receptors.
|
-
- HY-12462
-
-
- HY-103662
-
-
- HY-B1052A
-
-
- HY-12761
-
-
- HY-14261S
-
-
- HY-13713
-
-
- HY-B0287
-
|
Clofibrate
|
PPAR
|
Metabolic Disease
|
|
Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.
|
-
- HY-14824
-
|
Sofiniclin
ABT 894
|
nAChR
|
Neurological Disease
|
|
Sofiniclin (ABT 894), an agonist of nicotinic acetylcholine receptor (nAChR), is used as a potential non-stimulant research for attention-deficit/hyperactivity disorder (ADHD).
|
-
- HY-111498A
-
-
- HY-15697
-
-
- HY-15484
-
-
- HY-15382
-
-
- HY-125946
-
-
- HY-121251
-
-
- HY-10626
-
|
T0901317
|
LXR
FXR
ROR
Apoptosis
|
Cancer
Metabolic Disease
Cardiovascular Disease
|
|
T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα. T0901317 activates FXR with an EC50 of 5 μM. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice.
|
-
- HY-P1321A
-
|
GR231118 TFA
1229U91 TFA; GW1229 TFA
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8).
|
-
- HY-10013B
-
-
- HY-13556A
-
|
Arzoxifene hydrochloride
LY 353381 HCl; SERM 3
|
Estrogen Receptor/ERR
|
Cancer
|
|
Arzoxifene hydrocloride is a selective estrogen receptor modulator that is a potent estrogen antagonist in mammary and uterine tissue while acting as an estrogen agonist to maintain bone density and lower serum cholesterol.
|
-
- HY-B0031S1
-
-
- HY-100441
-
-
- HY-P1308
-
-
- HY-12381
-
|
ML224
NCGC00242364; ANTAG3
|
TSH Receptor
|
Endocrinology
|
|
ML224(NCGC00242364; ANTAG3) is a selective TSHR inverse agonist; inhibits TSH-stimulated cAMP production with an IC50 = 2.3 μM.
|
-
- HY-13740
-
-
- HY-P1752
-
-
- HY-104049
-
|
Lanifibranor
IVA337
|
PPAR
|
Metabolic Disease
Cancer
|
|
Lanifibranor is a pan peroxisome proliferator-activated receptor (PPAR) agonist with EC50s of 1.5, 0.87 and 0.21 μM for human PPARα, PPARσ and PPARγ, respectively.
|
-
- HY-N0361
-
|
Dihydrocapsaicin
|
TRP Channel
|
Metabolic Disease
|
|
Dihydrocapsaicin is a natural capsaicin, acts as a selective TRPV1 agonist, and also increases p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection.
|
-
- HY-10013A
-
-
- HY-15483
-
|
DY131
GSK 9089
|
Estrogen Receptor/ERR
|
Cancer
|
|
DY131(GSK 9089) is a novel selective agonist of ERRβ and ERRγ; displays minimal activity at ERRα, ERα and ERβ at concentrations up to 30 μM.
|
-
- HY-P2287
-
|
Cortagine
|
CRFR
|
Neurological Disease
|
|
Cortagine is a specific corticotropin-releasing factor receptor subtype 1 (CRF1) agonist with an IC50 of 2.6 nM for rCRF1. Cortagine is an anxiolytic and antidepressive drug in the mouse model.
|
-
- HY-105634
-
|
Nomegestrol
|
Progesterone Receptor
|
Endocrinology
|
|
Nomegestrol is a potent and orally available progestin, acts as a selective full progesterone receptor agonist, with a Kd of 5.44 nM for rat uterine progesterone receptor, and has moderate antiandrogenic activity and strong antiestrogenic activity.
|
-
- HY-101907
-
-
- HY-B0524A
-
-
- HY-101372A
-
|
Oxotremorine M iodide
|
mAChR
|
Neurological Disease
|
|
Oxotremorine M iodide is a potent and non-selective muscarinic acetylcholine receptor (mAChR) agonist. Oxotremorine M iodide potentiates NMDA receptors by muscarinic receptor dependent and independent mechanisms.
|
-
- HY-13715B
-
-
- HY-U00435
-
-
- HY-131103S
-
-
- HY-N0132A
-
-
- HY-17453
-
-
- HY-N0132
-
-
- HY-17038S
-
-
- HY-13956
-
|
Pioglitazone
U 72107
|
PPAR
Ferroptosis
|
Metabolic Disease
Cancer
|
|
Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
|
-
- HY-103698A
-
-
- HY-P1314A
-
-
- HY-10678
-
|
BMS-687453
|
PPAR
|
Cardiovascular Disease
|
|
BMS-687453 is a potent and selective PPARα agonist, with an EC50 and IC50 of 10 nM and 260 nM for human PPARα and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.
|
-
- HY-12434
-
-
- HY-18295
-
-
- HY-P0288
-
-
- HY-18286
-
|
NCGC00229600
|
TSH Receptor
|
Endocrinology
|
|
NCGC00229600 is an allosteric inverse agonist of thyrotropin receptor (TSHR). NCGC00229600 inhibits both TSH and stimulating antibody activation of TSHRs endogenously expressed in Graves' disease.
|
-
- HY-N3977
-
|
Grifolic acid
|
GPR120
|
Inflammation/Immunology
|
|
Grifolic acid is a phenolic compound that is first extracted from the mushroom Albatrellus confluens. Grifolic acid acts as an agonist of the free fatty acid receptor (FFAR4/GPR120).
|
-
- HY-P0199
-
-
- HY-19752A
-
-
- HY-115644
-
|
BMS-470539 dihydrochloride
|
Melanocortin Receptor
|
Inflammation/Immunology
|
|
BMS-470539 dihydrochloride is a highly potent and selective melanocortin-1 receptor (MC-1R) agonist with an IC50 of 120 nM, an EC50 of 28 nM. BMS-470539 dihydrochloride does not activate MC-3R and is a very weak partial agonist at MC-4R and MC-5R. BMS-470539 dihydrochloride has potently anti-inflammatory properties.
|
-
- HY-P1321
-
|
GR231118
1229U91; GW1229
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8).
|
-
- HY-107094
-
-
- HY-101454
-
-
- HY-108741A
-
-
- HY-101325
-
-
- HY-14417A
-
-
- HY-112219A
-
-
- HY-P1502
-
|
β-Endorphin, human
|
Opioid Receptor
|
Neurological Disease
|
|
β-Endorphin, human, a prominent endogenous peptide, existing in the hypophysis cerebri and hypothalamus, is an agonist of opioid receptor, with preferred affinity for μ-opioid receptor and δ-opioid receptor; β-Endorphin, human exhibits antinociception activity.
|
-
- HY-15701
-
-
- HY-P1180
-
-
- HY-120384
-
|
AZD-0284
|
ROR
|
Inflammation/Immunology
|
|
AZD-0284 is a selective inverse agonist of the nuclear receptor RORγ. AZD-0284 has the potential for plaque psoriasis vulgaris and respiratory tract disorders treatment.
|
-
- HY-100271
-
|
Org41841
|
TSH Receptor
|
Endocrinology
|
|
Org41841 is a partial agonist of both luteinizing hormone/chorionic gonadotropin receptor (LHCGR) and thyroid-stimulating hormone receptor (TSHR) with EC50s of 0.2 and 7.7 μM, respectively.
|
-
- HY-101085
-
|
SKL2001
|
Wnt
β-catenin
|
Cancer
|
|
SKL2001 is an agonist of the Wnt/β-catenin pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction.
|
-
- HY-15606
-
|
Tanaproget
NSP-989
|
Progesterone Receptor
|
Endocrinology
|
|
Tanaproget (NSP-989) is a novel nonsteroidal progesterone receptor agonist which can bind to the PR from various species with a higher relative affinity than reference steroidal progestins.
|
-
- HY-14554
-
|
LY2140023
|
mGluR
|
Neurological Disease
|
|
LY2140023 is an orally active prodrug of LY404039. LY404039 is a selective metabotropic glutamate 2/3 receptor agonist. LY2140023 has the potential for schizophrenia.
|
-
- HY-U00450
-
-
- HY-16673
-
|
PSN632408
|
GPR119
|
Metabolic Disease
|
|
PSN632408 is an optimized agonist of GPR119 receptors that shows similar potency to OEA at both recombinant mouse and human GPR119 receptors, exhibiting EC50 values of 5.6 and 7.9 uM, respectively.
|
-
- HY-P1752A
-
-
- HY-106147
-
|
Frakefamide
|
Opioid Receptor
|
Neurological Disease
|
|
Frakefamide is a potent analgesic that acts as a peripheral active μ-selective receptor agonist. Frakefamide is unable to penetrate the blood-brain-barrier and enter the central nervous system.
|
-
- HY-19381
-
-
- HY-19483
-
-
- HY-19937
-
|
Saroglitazar
|
PPAR
|
Metabolic Disease
|
|
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
|
-
- HY-A0279A
-
|
Pristinamycin IA
Mikamycin B; Mikamycin IA
|
Bacterial
|
Others
|
|
Pristinamycin IA (Mikamycin B;Mikamycin IA), a biologically active decapeptide isolated from the skin of the Australian frog Hyla caerulea, is a potent cholecystokinetic agent, and acts as a cholecystokinin receptor agonist.
|
-
- HY-13008
-
-
- HY-N6691
-
|
Veratridine
3-Veratroylveracevine
|
Sodium Channel
|
Neurological Disease
|
|
Veratridine (3-Veratroylveracevine), a alkaloid derived from plants in the family Liliaceae, is a sodium channel agonist. Veratridine inhibits the peak current of Nav1.7, with an IC50 of 18.39 µM.
|
-
- HY-18936
-
-
- HY-103546
-
-
- HY-N0049
-
|
Nuciferine
|
5-HT Receptor
Dopamine Receptor
|
Neurological Disease
|
|
Nuciferine is an antagonist at 5-HT2A (IC50=478 nM), 5-HT2C (IC50=131 nM), and 5-HT2B (IC50=1 μM), an inverse agonist at 5-HT7 (IC50=150 nM), a partial agonist at D2 (EC50=64 nM), D5 (EC50=2.6 μM) and 5-HT6 (EC50=700 nM), an agonist at 5-HT1A (EC50=3.2 μM) and D4 (EC50=2 μM) receptor.
|
-
- HY-10349A
-
|
WAY-100635 Maleate
|
5-HT Receptor
Dopamine Receptor
|
Neurological Disease
|
|
WAY-100635 maleate is a potent and selective 5-hydroxytryptamine 1A (5-HT1A) receptor antagonist with an IC50 value of 0.91 nM and Ki value of 0.39 nM. WAY-100635 maleate has pIC50 values for 5-HT1A and α1-adrenergic receptors of 8.9 and 6.6, respectively. WAY-100635 maleate is also a potent dopamine D4 receptor agonist.
|
-
- HY-119222
-
|
GSK256073
|
GPR109A
|
Metabolic Disease
|
|
GSK256073 is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia. GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2
|
-
- HY-103409
-
|
ABT-724 trihydrochloride
|
Dopamine Receptor
|
Neurological Disease
|
|
ABT-724 trihydrochloride is a potent and highly selective dopamine D4 receptor agonist with an EC50 of 12.4 nM for human dopamine D4 receptor. ABT-724 trihydrochloride is a potent partial agonist at the rat D4 (EC50 of 14.3 nM) and the ferret D4 receptor (EC50 of 23.2 nM), and has no effect on dopamine D1, D2, D3, or D5 receptors. ABT-724 trihydrochloride could be useful for the treatment of erectile dysfunction and has favorable side-effect profile.
|
-
- HY-12707
-
-
- HY-114118
-
-
- HY-17043
-
-
- HY-P1180A
-
-
- HY-104070
-
|
LG-100064
|
RAR/RXR
Autophagy
|
Cancer
|
|
LG-100064 is a retinoid-X-receptor (RXR) agonist, with EC50s of 330 nM, 200 nM, and 260 nM for RXRα, RXRβ and RXRγ; LG-100064 can be used in the research of cancer.
|
-
- HY-12365
-
|
Namodenoson
CF-102; 2-Cl-IB-MECA
|
Adenosine Receptor
|
Cancer
|
|
Namodenoson (CF-102) is a selective A3 adenosine receptor agonist (Ki = 0.33 nM). Displays 2500- and 1400-fold selectivity over A1 and A2A receptors respectively.
|
-
- HY-106157
-
-
- HY-P1160
-
-
- HY-G0014
-
|
Quetiapine sulfoxide
Quetiapine S-oxide
|
Drug Metabolite
|
Neurological Disease
|
|
Quetiapine sulfoxide (Quetiapine S-oxide) is a main metabolite of Quetiapinem. Quetiapine is a second-generation antipsychotic. Quetiapine is a 5-HT receptors agonist and a dopamine receptor antagonist.
|
-
- HY-N2148
-
|
Cytosporone B
Csn-B; Dothiorelone G
|
Others
|
Cancer
|
|
Cytosporone B (Csn-B; Dothiorelone G) is a naturally occurring nuclear orphan receptor Nur77/NR4A1 agonist with an EC50 of 0.278 nM.
|
-
- HY-103252
-
-
- HY-100443A
-
-
- HY-P1016A
-
-
- HY-G0014B
-
-
- HY-14221
-
|
Siramesine
Lu 28-179
|
Sigma Receptor
Ferroptosis
|
Cancer
|
|
Siramesine(Lu 28-179) is a selective sigma-2 receptor agonist, which has been shown to trigger cell death of cancer cells and to exhibit a potent anticancer activity in vivo.
|
-
- HY-G0014A
-
-
- HY-19937A
-
|
Saroglitazar Magnesium
|
PPAR
|
Metabolic Disease
|
|
Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
|
-
- HY-18678A
-
-
- HY-17034
-
-
- HY-14221A
-
|
Siramesine hydrochloride
Lu 28-179 hydrochloride
|
Sigma Receptor
Ferroptosis
|
Cancer
|
|
Siramesine hydrochloride (Lu 28-179 hydrochloride) is a selective sigma-2 receptor agonist, which has been shown to trigger cell death of cancer cells and to exhibit a potent anticancer activity in vivo.
|
-
- HY-107982
-
|
VU6005649
|
mGluR
|
Neurological Disease
|
|
VU6005649 is a CNS penetrant mGlu7/8 receptor agonist with EC50s of 0.65 μM and 2.6 μM for mGlu7 receptor and mGlu8 receptor, respectively.
|
-
- HY-15043
-
-
- HY-131106S
-
-
- HY-A0010
-
-
- HY-12560D
-
-
- HY-15655
-
-
- HY-10680
-
|
MK-6892
|
GPR109A
|
Cancer
|
|
MK-6892 is a potent, selective, and full agonist for the high affinity nicotinic acid (NA) receptor GPR109A. Ki and GTPγS EC50 of MK-6892 on the Human GPR109A is 4 nM and 16 nM, respectively.
|
-
- HY-106147B
-
|
Frakefamide TFA
|
Opioid Receptor
|
Neurological Disease
|
|
Frakefamide TFA is a potent analgesic that acts as a peripheral active μ-selective receptor agonist. Frakefamide is unable to penetrate the blood-brain-barrier and enter the central nervous system.
|
-
- HY-111343
-
|
ONC212
|
Apoptosis
|
Cancer
Endocrinology
|
|
ONC212, a fluorinated-ONC201 analogue, is a promising anti-cancer agent and also a selective agonist of GPR132. ONC212 also induces apoptosis.
|
-
- HY-103005
-
-
- HY-112606
-
|
ML-290
|
Others
|
Others
|
|
ML-290 is a first-in-class and potent relaxin/insulin-like family peptide receptor (RXFP1) agonist and activator of anti-fibrotic genes, with an EC50 of 94 nM.
|
-
- HY-N0163
-
-
- HY-12641
-
|
Pyrantel tartrate
|
Parasite
Antibiotic
|
Infection
|
|
Pyrantel tartrate is an antinematodal thiophene; nicotinic receptor agonist and can elicit spastic muscle paralysis in parasitic worms due to prolonged activation of the excitatory nicotinic acetylcholine (nACh) receptors on body wall muscle.
|
-
- HY-P1308A
-
-
- HY-15124
-
-
- HY-19650
-
-
- HY-110238
-
|
MK6-83
|
TRP Channel
|
Metabolic Disease
|
|
MK6-83 is a new candidate agonist of TRPML1 with an improved efficacy and potency. MK6-83 has the potential for Mucolipidosis type IV study.
|
-
- HY-111809
-
-
- HY-B0820
-
|
Nitenpyram
|
nAChR
|
Neurological Disease
|
|
Nitenpyram is a calss of neonicotinoid and an insect nicotinic acetylcholine receptor (nAChR) agonist with an IC50 of 14 nM. Nitenpyram is an oral fast-acting insecticide used to suppress sucking insects on companion animals.
|
-
- HY-19870
-
-
- HY-P1317
-
-
- HY-P0186A
-
-
- HY-105170B
-
|
ABT-418 hydrochloride
|
nAChR
|
Neurological Disease
|
|
ABT-418 hydrochloride is a potent and selective agonist of nAChRs with cognitive enhancing and anxiolytic activities. ABT-418 hydrochloride activates cholinergic channel and can be used for research of Alzheimer's disease.
|
-
- HY-13463
-
-
- HY-106025
-
|
Radequinil
AC-3933
|
GABA Receptor
|
Neurological Disease
|
|
Radequinil (AC-3933) is a benzodiazepine receptor (BzR) partial inverse agonist. AC-3933 binds to GABA(-) and GABA(+) ligand with Kis of 5.15 and 6.11 nM, respectively.
|
-
- HY-18941
-
|
Eglumegad
LY354740; Eglumetad
|
mGluR
|
Neurological Disease
|
|
Eglumegad (LY354740) is a highly potent and selective group II (mGlu2/3) receptor agonist with IC50s of 5 and 24 nM on transfected human mGlu2 and mGlu3 receptors, respectively.
|
-
- HY-P1125
-
|
4-CMTB
|
Others
|
Others
|
|
4-CMTB is a selective free fatty acid receptor 2 (FFA2/GPR43) agonist and a positive allosteric modulator (pEC50=6.38).
|
-
- HY-17416
-
-
- HY-18760
-
|
LY2812223
|
mGluR
|
Neurological Disease
|
|
LY2812223 is a highly potent, functionally selective mGlu2 receptor agonist with mGlu2 binding affinity for mGlu2 and mGlu3 (Ki=144 nM and 156 nM, respectively).
|
-
- HY-100815B
-
|
(RS)-AMPA
(±)-AMPA
|
iGluR
|
Neurological Disease
|
|
(RS)-AMPA ((±)-AMPA) is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA does not interfere with binding sites for kainic acid or NMDA receptors.
|
-
- HY-103007
-
-
- HY-107094A
-
-
- HY-19870B
-
-
- HY-100806
-
-
- HY-135392
-
|
N-Desmethyl Pimavanserin
AC-279
|
Drug Metabolite
|
|
|
N-Desmethyl Pimavanserin is the active metabolite of Pimavanserin. Pimavanserin is a selective inverse agonist of the 5-HT2A receptor with pIC50 and pKd of 8.73 and 9.3, respectively.
|
-
- HY-19383
-
|
Ertiprotafib
PTP 112
|
Phosphatase
IKK
PPAR
|
Metabolic Disease
|
|
Ertiprotafib is an inhibitor of PTP1B, IkB kinase β (IKK-β), and a dual PPARα and PPARβ agonist, with an IC50 of 1.6 μM for PTP1B, 400 nM for IKK-β, an EC50 of ~1 μM for PPARα/PPARβ.
|
-
- HY-B0471
-
-
- HY-14608
-
-
- HY-U00036A
-
|
Naveglitazar
LY519818
|
PPAR
|
Metabolic Disease
|
|
Naveglitazar (LY519818) is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models.
|
-
- HY-107773
-
|
GSK3004774
|
CaSR
|
Metabolic Disease
|
|
GSK3004774 is a potent, nonabsorbable agonist of CaSR, with an pEC50 of 7.3, 6.6 and 6.5 for human, mouse and rat CaSR, respectively. GSK3004774 shows an EC50 of 50 nM for human CaSR.
|
-
- HY-107512
-
-
- HY-12694
-
-
- HY-123291
-
-
- HY-13410
-
|
Xanomeline oxalate
LY246708 oxalate
|
mAChR
|
Neurological Disease
|
|
Xanomeline oxalate (LY246708 oxalate) is a potent and selective muscarinic receptor agonist (SMRA) and stimulates phosphoinositide hydrolysis in vivo. Xanomeline oxalate can be used for the research of Alzheimer’s disease.
|
-
- HY-13928
-
-
- HY-110241
-
|
Dianicline dihydrochloride
|
nAChR
|
Neurological Disease
|
|
Dianicline dihydrochloride is a α4β2 nicotinic acetylcholine receptor partial agonist, a class of drugs that includes varenicline and cytisine for smoking cessation. Dianicline dihydrochloride increases cessation rates in a dose-dependent manner.
|
-
- HY-14546S
-
-
- HY-W013372
-
-
- HY-N0164
-
|
Matrine
Matridin-15-one; Vegard; α-Matrine
|
Opioid Receptor
Autophagy
Mitophagy
|
Cancer
|
|
Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus. It has a variety of pharmacological effects, including anti-cancer effects, and action as a kappa opioid receptor and u-receptor agonist.
|
-
- HY-16639
-
-
- HY-135270
-
-
- HY-14330
-
|
ABT-724
|
Dopamine Receptor
|
Neurological Disease
|
|
ABT-724 is a potent and highly selective dopamine D4 receptor agonist with an EC50 of 12.4 nM for human dopamine D4 receptor. ABT-724 is a potent partial agonist at the rat D4 (EC50 of 14.3 nM) and the ferret D4 receptor (EC50 of 23.2 nM). ABT-724 has no effect on dopamine D1, D2, D3, or D5 receptors. ABT-724 could be useful for the treatment of erectile dysfunction and has favorable side-effect profile.
|
-
- HY-B1658A
-
|
Frovatriptan succinate hydrate
|
5-HT Receptor
|
Neurological Disease
|
|
Frovatriptan succinate hydrate is a potent, high affinity, selective and orally active 5-HT1B, HT1D receptor agonist and a moderately potent 5-HT7 receptor agonist, with pKi values of 8.6, 8.4, and 6.7, respectively. Frovatriptan succinate hydrate is effective in treating the full spectrum of migraine including the associated symptoms of nausea, vomiting, photophobia, and phonophobia. Frovatriptan succinate hydrate can also be used as in mini-prophylaxis in menstrual migraine.
|
-
- HY-116214
-
|
Cyprodinil
|
Fungal
Androgen Receptor
|
|
|
Cyprodinil is an anilinopyrimidine broad-spectrum fungicide that inhibits the biosynthesis of methionine in phytopathogenic fungi. Cyprodinil inhibits mycelial cell growth of B. cinerea, P. herpotrichoides, and H. oryzae on amino acid-free media (IC50s=0.44, 4.8, and 0.03 µM, respectively). Cyprodinil acts as an androgen receptor (AR) agonist (EC50=1.91 µM) in the absence of the AR agonist DHT and inhibits the androgenic effect of DHT (IC50=15.1 µM).
|
-
- HY-101514
-
-
- HY-111763
-
-
- HY-A0181A
-
-
- HY-105124A
-
-
- HY-128770
-
-
- HY-P1296
-
|
Urocortin, rat
Urocortin (Rattus norvegicus); Rat urocortin
|
CRFR
|
Neurological Disease
Endocrinology
|
|
Urocortin, rat (Urocortin (Rattus norvegicus)) is a neuropeptide and a potent endogenous CRFR agonist with Kis of 13 nM, 1.5 nM, and 0.97 nM for human CRF1, rat CRF2α and mouse CRF2β, respectively.
|
-
- HY-10957
-
|
L-692429
MK-0751
|
Others
|
Metabolic Disease
|
|
L-692429 (MK-0751) is a benzolactam derivative and a nonpeptidyl growth hormone secretagogue (GHS) agonist. L-692429 binds to G protein-coupled receptor with a Ki of 63 nM.
|
-
- HY-N6642
-
|
Ankaflavin
|
PPAR
|
Cancer
Inflammation/Immunology
|
|
Ankaflavin, isolated from Monascus-Fermented red rice, is a PPARγ agonist with anti-inlfammatory activity. Ankaflavin exhibits selective cytotoxic effect and induces cell death on cancer cells.
|
-
- HY-14296
-
-
- HY-10622
-
-
- HY-P1295
-
|
Urocortin, human
Urocortin (human); Human urocortin; Human urocortin 1; Human urocortin I
|
CRFR
|
Neurological Disease
Endocrinology
|
|
Urocortin, human, a 40-aa neuropeptide, acts as a selective agonist of endogenous CRF2 receptor, with Kis of 0.4, 0.3, and 0.5 nM for hCRF1, rCRF2α and mCRF2β, respectively.
|
-
- HY-118504
-
|
Sulfoxaflor
|
nAChR
|
Neurological Disease
|
|
Sulfoxaflor is a sulfoximine insecticide and is an agonist of nAChR1 and nAChR2 subtypes. Sulfoxaflor is used for the control of sap-feeding insects such as Myzus persicae, Aphis gossypii, Bemissia tabaci and Nilaparvata lugens.
|
-
- HY-112217A
-
|
PSEM 89S TFA
|
nAChR
|
Neurological Disease
|
|
PSEM 89S TFA is a selective and brain penetrant agonists for the resulting ion channels. PSEM 89S TFA is orthogonally selective for Q79G and L141F, respectively.
|
-
- HY-B1276A
-
-
- HY-114118A
-
-
- HY-P1160A
-
-
- HY-14262
-
-
- HY-108525
-
|
Fluorobexarotene
|
RAR/RXR
|
Cancer
|
|
Fluorobexarotene (compound 20) is a potent retinoid-X-receptor (RXR) agonist, with a Ki value of 12 nM and an EC50 value of 43 nM for RXRα receptor. Fluorobexarotene possesses an apparent RXR binding affinity that is 75% greater than Bexarotene.
|
-
- HY-14608A
-
-
- HY-100300
-
-
- HY-N6825
-
-
- HY-14649
-
|
Retinoic acid
Vitamin A acid; all-trans-Retinoic acid; ATRA
|
RAR/RXR
PPAR
Endogenous Metabolite
Autophagy
|
Cancer
|
|
Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM.
|
-
- HY-19522A
-
|
Seladelpar sodium salt
MBX-8025 sodium salt; RWJ-800025 sodium salt
|
PPAR
|
Metabolic Disease
|
|
Seladelpar sodium salt (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM, showing more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively.
|
-
- HY-19733
-
-
- HY-112692
-
|
AT-121
|
Opioid Receptor
|
Neurological Disease
|
|
AT-121 is a bifunctional nociception and mu opioid receptor agonist, with Kis of 3.67 and 16.49 nM, respectively. AT-121 is a safe, non-addictive analgesic, and shows antinociceptive and antiallodynic effects.
|
-
- HY-N0170
-
-
- HY-16056
-
|
Arbutamine
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Arbutamine is a short-acting, potent and nonselective β-adrenoceptor agonist that increases heart rate, cardiac contractility, and systolic blood pressure. Arbutamine is a catecholamine for a pharmacological cardiac stress agen.
|
-
- HY-17642
-
|
Omidenepag
|
Prostaglandin Receptor
|
Endocrinology
|
|
Omidenepag,a pharmacologically active form of Omidenepag Isopropyl, is a selective, non-prostanoid EP2 receptor agonist, with an EC50 of 1.1 nM. Omidenepag shows binding affinities (IC50) 10 nM for h-EP2.
|
-
- HY-133113
-
-
- HY-19870A
-
-
- HY-P1731
-
|
Tirzepatide
LY3298176
|
Glucagon Receptor
|
Metabolic Disease
|
|
Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes.
|
-
- HY-124733A
-
-
- HY-19864
-
|
Aganepag
AGN 210937
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
Aganepag is a potent Prostanoid EP2 receptor agonist, with an EC50 of 0.19 nM, and shows no activity at EP4 receptor. Aganepag can be used in the research of wound healing, scar reduction, scar prevention and wrinkle treatment and prevention.
|
-
- HY-117516
-
|
SR10067
|
Others
|
Neurological Disease
|
|
SR10067 is a potent, selective and brain penetrant Rev-Erbα/β agonist, with IC50 values are 160 and 170 nM for Rev-Erbβ and Rev-Erbα, respectively. SR10067 has anxiolytic activity.
|
-
- HY-103178
-
|
MRE3008F20
|
Adenosine Receptor
|
Cancer
|
|
MRE3008F20 is a highly potent and selective antagonist of adenosine A3 receptor (AA3R), inhibiting agonist-induced cAMP elevation in resting T lymphocytes with an IC50 of 5 nM.
|
-
- HY-112692A
-
|
AT-121 hydrochloride
|
Opioid Receptor
|
Neurological Disease
|
|
AT-121 hydrochloride is a bifunctional nociception and mu opioid receptor agonist, with Kis of 3.67 and 16.49 nM, respectively. AT-121 hydrochloride is a safe, non-addictive analgesic, and shows antinociceptive and antiallodynic effects.
|
-
- HY-P1731B
-
|
Tirzepatide hydrochloride
LY3298176 hydrochloride
|
Glucagon Receptor
|
Metabolic Disease
|
|
Tirzepatide hydrochloride (LY3298176 hydrochloride) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes.
|
-
- HY-12222
-
|
Obeticholic acid
INT-747; 6-ECDCA; 6-Ethylchenodeoxycholic acid
|
FXR
Autophagy
|
Others
|
|
Obeticholic acid (INT-747) is a potent, selective and orally active FXR agonist with an EC50 of 99 nM. Obeticholic acid has anticholeretic and anti-inflammation effect. Obeticholic acid also induces autophagy.
|
-
- HY-10061
-
|
Lesogaberan
AZD-3355
|
GABA Receptor
|
Metabolic Disease
|
|
Lesogaberan (AZD-3355) is a potent and selective GABAB receptor agonist with an EC50 of 8.6 nM for human recombinant GABAB receptors. Binding affinity (Kis) of 5.1 nM and 1.4 μM for rat brain GABAB and GABAA receptors, respectively.
|
-
- HY-101370
-
-
- HY-108649A
-
-
- HY-P1540
-
-
- HY-108529
-
|
BMS493
|
RAR/RXR
|
Metabolic Disease
|
|
BMS493 is an inverse pan-retinoic acid receptor (RAR) agonist. BMS493 increases nuclear corepressor interaction with RARs. BMS493 also could prevent retinoic acid-induced differentiation.
|
-
- HY-110000
-
-
- HY-128064
-
-
- HY-117071
-
-
- HY-U00036
-
|
Naveglitazar racemate
LY519818 racemate
|
PPAR
|
Metabolic Disease
|
|
Naveglitazar racemate (LY519818 racemate) is the racemate of Naveglitazar. Naveglitazar is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models.
|
-
- HY-136290
-
-
- HY-B1500
-
-
- HY-103181
-
-
- HY-B2054
-
|
Tebufenozide
|
Apoptosis
|
Others
|
|
Tebufenozide is a nonsteroidal ecdysone agonist used to control pest. Tebufenozide has cytotoxic and induces apoptosis in HeLa and insect Tn5B1-4 cells.
|
-
- HY-113970A
-
|
Nebracetam hydrochloride
WEB 1881 FU hydrochloride
|
mAChR
|
Neurological Disease
|
|
Nebracetam hydrochloride, a nootropic M1-muscarinic agonist, induces a rise of intracellular Ca 2+ concentration. Nebracetam hydrochloride exhibits an EC50 of 1.59 mM for elevating [Ca 2+]i.
|
-
- HY-B0982
-
-
- HY-12685
-
|
Ceralifimod
ONO-4641
|
LPL Receptor
|
Neurological Disease
|
|
Ceralifimod (ONO-4641) is selective, high potent agonist for sphingosine 1-phosphate receptors 1 and 5, with EC50s of 27.3, 334 pM for human S1P receptor 1 and 5, respectively.
|
-
- HY-19608
-
-
- HY-12560A
-
|
PNU-282987
|
nAChR
|
Neurological Disease
|
|
PNU-282987 is a selective α7 nicotinic acetylcholine receptor(α7 nAChR) agonist with Ki of 26 nM; no affinity for α1β1γδ and α3β4 nAChRs (IC50 ≥ 60 μM).
|
-
- HY-15682
-
|
TTNPB
Ro 13-7410; Arotinoid acid; AGN191183
|
RAR/RXR
Autophagy
Apoptosis
|
Cancer
|
|
TTNPB is a highly potent RAR agonist. Competitive binding assays using human RARs yield IC50s of α=5.1 nM, β= 4.5 nM, and γ=9.3 nM, respectively.
|
-
- HY-P1418
-
|
DPC-AJ1951
|
Thyroid Hormone Receptor
|
Endocrinology
|
|
DPC-AJ1951, a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR) , and characterized its activity in ex vivo and in vivo assays of bone resorption.
|
-
- HY-135119
-
|
Salmeterol-D3
|
Adrenergic Receptor
|
|
|
Salmeterol-D3 is the deuterium labeled Salmeterol (HY-14302). Salmeterol is a long-acting beta2-adrenergic receptor agonist that is used for the study of asthma and chronic obstructive pulmonary disease (COPD).
|
-
- HY-N6868
-
-
- HY-P1132
-
-
- HY-109137
-
|
Selgantolimod
GS-9688
|
Toll-like Receptor (TLR)
HBV
|
Infection
|
|
Selgantolimod (GS-9688) is an orally active, potent and selective toll-like receptor 8 (TLR8) agonist for the treatment of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection.
|
-
- HY-111582
-
|
BBIQ
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of 59.1 nM for human TLR7. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses.
|
-
- HY-P1348
-
-
- HY-12288
-
-
- HY-128344
-
|
BR102375
|
PARP
Apoptosis
|
Metabolic Disease
|
|
BR102375 is a non-TZD peroxisome proliferator-activated receptor γ (PPAR γ) full agonist for the treatment of type 2 diabetes, reveals EC50 value of 0.28 μM and Amax ratio of 98%.
|
-
- HY-P1167
-
-
- HY-P1296A
-
|
Urocortin, rat TFA
Urocortin (Rattus norvegicus) (TFA); Rat urocortin TFA
|
CRFR
|
Endocrinology
Neurological Disease
|
|
Urocortin, rat TFA (Urocortin (Rattus norvegicus) TFA) is a neuropeptide and a potent endogenous CRFR agonist with Kis of 13 nM, 1.5 nM, and 0.97 nM for human CRF1, rat CRF2α and mouse CRF2β, respectively.
|
-
- HY-100330
-
-
- HY-N0630
-
-
- HY-12764
-
|
6-OAU
GTPL5846
|
GPR84
|
Inflammation/Immunology
|
|
6-OAU(GTPL5846; 6-n-octylaminouracil) is a surrogate agonist of GPR84; activates human GPR84 in the presence of Gqi5 chimera in HEK293 cells with an EC50 of 105 nM in the PI assay.
|
-
- HY-14171S
-
|
Bexarotene D4
LGD1069 D4
|
RAR/RXR
Autophagy
|
Cancer
|
|
Bexarotene D4 is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma.
|
-
- HY-P1537
-
-
- HY-18779
-
|
PF-4840154
|
TRP Channel
|
Inflammation/Immunology
|
|
PF-4840154 is a potent, selective agonist of the rat and human TrpA1 channel with EC50s of 97 and 23 nM, respectively. PF-4840154 elicits TrpA1-mediated nocifensive behaviour in mouse.
|
-
- HY-P1418A
-
|
DPC-AJ1951 TFA
|
Thyroid Hormone Receptor
|
Endocrinology
|
|
DPC-AJ1951 TFA, a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR) , and characterized its activity in ex vivo and in vivo assays of bone resorption.
|
-
- HY-B1276
-
-
- HY-112707
-
-
- HY-70081A
-
|
Sumanirole maleate
U-95666E; PNU-95666
|
Dopamine Receptor
|
Neurological Disease
|
|
Sumanirole maleate (U-95666E; PNU-95666E) is a highly selective D2 receptor full agonist with an ED50 of about 46 nM. Sumanirole was developed for the treatment of Parkinson's disease and restless leg syndrome.
|
-
- HY-P1132A
-
-
- HY-135895
-
-
- HY-13225A
-
|
Rivanicline
RJR-2403; (E)-Metanicotine
|
nAChR
|
Neurological Disease
|
|
Rivanicline (RJR-2403; (E)-Metanicotine) is a neuronal nicotinic receptor agonist, showing high selectivity for the α4β2 subtype (Ki=26 nM); > 1,000 fold selectivity than α7 receptors(Ki= 36000 nM).
|
-
- HY-100689
-
|
Propyl pyrazole triol
PPT
|
Estrogen Receptor/ERR
|
Cancer
|
|
Propyl pyrazole triol (PPT) is a selective estrogen receptor alpha (ERα) agonist. The relative binding affinity of Propyl pyrazole triol for ERα (ERα: 49%) around 410 times higher compared with estrogen receptor beta (ERβ: 0.12%).
|
-
- HY-P1279
-
-
- HY-100781A
-
|
L-APB
L-AP 4
|
mGluR
|
Neurological Disease
|
|
L-APB is a potent and specific agonist for the group III mGluRs, with EC50s of 0.13, 0.29, 1.0, 249 μM for mGlu4, mGlu8, mGlu6 and mGlu7 receptors, respectively.
|
-
- HY-100013A1
-
-
- HY-B1675
-
|
Levalbuterol
(R)-Albuterol; (R)-Salbutamol; Levosalbutamol
|
Adrenergic Receptor
|
Inflammation/Immunology
|
|
Levalbuterol ((R)-Albuterol; (R)-Salbutamol) is a short-acting β2-adrenergic receptor agonist and the active (R)-enantiomer of Salbutamol. Levalbuterol is a more potent bronchodilator than Salbutamol and has the potential for the treatment of COPD.
|
-
- HY-P1438
-
|
Neuropeptide S(Rat)
|
Neuropeptide Y Receptor
|
|
|
Neuropeptide S(Rat) is a potent endogenous neuropeptide S receptor (NSPR) agonist (EC50=3.2 nM). Neuropeptide S(Rat) increases locomotor activity and wakefulness in mice. Neuropeptide S(Rat) also reduces anxiety-like behavior in mice.
|
-
- HY-P1252
-
-
- HY-P1731A
-
|
Tirzepatide TFA
LY3298176 TFA
|
Glucagon Receptor
|
Metabolic Disease
|
|
Tirzepatide TFA (LY3298176 TFA) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes.
|
-
- HY-14848
-
|
Naluzotan
PRX 00023
|
5-HT Receptor
Potassium Channel
|
Neurological Disease
|
|
Naluzotan is a novel, potent, and selective amidosulfonamide 5-HT1A agonist with IC50 and Ki of appr 20 nM and 5.1 nM, used for the treatment of anxiety and depression; Also a weak hERG K + channel blocker, with IC50 of 3800 nM.
|
-
- HY-B0020
-
-
- HY-124401
-
|
BT-13
|
RET
|
Neurological Disease
|
|
BT-13 is a potent and selective glial cell line-derived neurotrophic factor (GDNF) receptor RET agonist independently of GFLs, promoting neurite growth from sensory neurons in vitro and attenuates experimental neuropathy in the Rat.
|
-
- HY-106993
-
|
Cipralisant
GT-2331
|
Histamine Receptor
|
Neurological Disease
Endocrinology
|
|
Cipralisant is a potent and selective histamine H3 receptor antagonist in vivo, and an agonist in vitro, with a pKi of 9.9 for histamine H3 receptor and a Ki of 0.47 nM for rat histamine H3 receptor; Cipralisant has the potential for attention-deficit hyperactivity disorder treatment.
|
-
- HY-N0301
-
|
Thiocolchicoside
|
GABA Receptor
|
Inflammation/Immunology
Neurological Disease
|
|
Thiocolchicoside is a competitive γ-aminobutyric acid type A (GABAA) receptor antagonist and glycine receptor agonist in the central nervous system. Thiocolchicoside is a semisynthetic sulfur derivative of colchicoside. Thiocolchicoside is a muscle relaxant and has anti-inflammatory, and analgesic properties.
|
-
- HY-126057S
-
|
(R)-Praziquantel D11
|
Parasite
5-HT Receptor
|
Infection
|
|
(R)-Praziquantel D11 is the deuterium labeled (R)-Praziquantel. (R)-Praziquantel, the active enantiomer of Praziquantel, is a partial agonist of the human 5-HT2B receptor. (R)-Praziquantel acts as an antischistosomal eutomer.
|
-
- HY-108661
-
|
NF546
|
P2Y Receptor
|
Inflammation/Immunology
|
|
NF546 is a selective non-nucleotide P2Y11 agonist with a pEC50 of 6.27. NF546 stimulates release of interleukin-8 from human monocyte-derived dendritic cells.
|
-
- HY-129658A
-
-
- HY-100176
-
-
- HY-121885
-
|
LMD-009
|
CCR
|
Metabolic Disease
Endocrinology
|
|
LMD-009 is a selective CCR8 nonpeptide agonist. LMD-009 mediates chemotaxis, inositol phosphate accumulation, and calcium release in high potencies with EC50s from 11 to 87 nM.
|
-
- HY-111455
-
|
LP-211
|
5-HT Receptor
|
Neurological Disease
|
|
LP-211 is a selective and blood−brain barrier penetrant 5-HT7 receptor agonist, with a Ki of 0.58 nM, with high selectivity over 5-HT1A receptor (Ki, 188 nM) and D2 receptor (Ki, 142 nM).
|
-
- HY-P7060
-
|
NT 13
TPPT
|
iGluR
|
Neurological Disease
|
|
NT 13 (TPPT) is a tetrapeptide having the amino acid sequence L-threonyl-L-prolyl-L-prolyl-L-threonine amide. NT 13 is a partial N-methyl-D-aspartate receptor (NMDAR) agonist used in the study of depression, anxiety, and other related diseases.
|
-
- HY-P1252A
-
-
- HY-122190
-
|
TAK-071
|
mAChR
|
Neurological Disease
|
|
TAK-071 is a novel, potent and highly selective muscarinic acetylcholine receptor 1 (M1R) positive allosteric modulator. EC50 of TAK-071 M1R agonist activities is 520 nM.
|
-
- HY-16687A
-
-
- HY-17609
-
|
Difelikefalin
CR-845; FE-202845
|
Opioid Receptor
|
Neurological Disease
|
|
Difelikefalin (CR-845; FE-202845) is a peripherally restricted and selective agonist of kappa opioid receptor (KOR). Difelikefalin produces anti-inflammatory effects and has the potential in modulating pruritus in conditions such as chronic kidney disease.
|
-
- HY-16995
-
-
- HY-P1167A
-
-
- HY-112706
-
|
PF-06747711
|
ROR
|
Inflammation/Immunology
|
|
PF-06747711 is a potent, selective, and orally active retinoic acid receptor-related orphan C2 (RORC2, also known as RORγt) inverse agonist, with an IC50 of 4.1 nM. Anti-skin inflammatory activity.
|
-
- HY-P1166
-
|
UFP-803
|
Urotensin Receptor
|
Cardiovascular Disease
|
|
UFP-803 is a potent urotensin-II receptor (UT) ligand. UFP-803 has lower residual agonist activity, so it may be an important tool for the investigations on the role played by the UT system in physiology and pathology.
|
-
- HY-113151
-
-
- HY-P1294
-
-
- HY-111547
-
|
M1001
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
M1001 is a weak agonist of HIF-2α, directly binds to the HIF-2α PAS-B domain, with a Kd of 667 nM. M1001 enhances the stabilities of HIF-2α-ARNT complex.
|
-
- HY-100807
-
-
- HY-N0285
-
|
Imperatorin
Ammidin
|
AChE
TRP Channel
|
Neurological Disease
|
|
Imperatorin is an effective of NO synthesis inhibitor (IC50=9.2 μmol), which also is a BChE inhibitor (IC50=31.4 μmol). Imperatorin is a weak agonist of TRPV1 with EC50 of 12.6±3.2 μM.
|
-
- HY-A0261
-
|
Pentagastrin
ICI-50123
|
Cholecystokinin Receptor
|
Cancer
Endocrinology
|
|
Pentagastrin (ICI-50123) is a selective agonist of Cholecystokinin B (CCKB) receptor with an IC50 of 11 nM. Pentagastrin enhances gastric mucosal defence mechanisms against acid and protects the gastric mucosa from experimental injury.
|
-
- HY-101310
-
|
SYM 2081
|
iGluR
|
Neurological Disease
|
|
SYM 2081 is a high-affinity ligand and potent, selective agonist of kainate receptors, inhibits [ 3H]-kainate binding with an IC50 of 35 nM, almost 3000- and 200-fold selectivity for kainate receptors over AMPA and NMDA receptors respectively.
|
-
- HY-P1124
-
|
AS2034178 free base
|
GPR40
|
Metabolic Disease
|
|
AS2034178 free base, a specific and orally active GPR40 agonist, exhibits glucose-dependent insulin secretion enhancement. AS2034178 free base has potential for type 2 diabetes mellitus research.
|
-
- HY-P1279A
-
-
- HY-103244
-
|
CITCO
|
Apoptosis
|
Cancer
|
|
CITCO, an imidazothiazole derivative, is a selective Constitutive androstane receptor (CAR) agonist. CITCO inhibits growth and expansion of brain tumour stem cells (BTSCs) and has an EC50 of 49 nM over pregnane X receptor (PXR), and no activity on other nuclear receptors.
|
-
- HY-116506
-
|
Bigelovin
|
RAR/RXR
Reactive Oxygen Species
Apoptosis
Autophagy
|
Cancer
|
|
Bigelovin, a sesquiterpene lactone isolated from Inula helianthus-aquatica, is a selective retinoid X receptor α agonist. Bigelovin suppresses tumor growth through inducing apoptosis and autophagy via the inhibition of mTOR pathway regulated by ROS generation.
|
-
- HY-12720A
-
|
Apraclonidine hydrochloride
ALO 2145
|
Others
|
Neurological Disease
|
|
Apraclonidine hydrochloride (ALO 2145), a selective α2 and weak α1 receptor agonist activity, effectively lowers intraocular pressure (IOP) in human eyes. Apraclonidine hydrochloride is a topical ophthalmic solution and has the ability to elevate the eye lid.
|
-
- HY-B0443A
-
-
- HY-124733
-
-
- HY-B0443
-
-
- HY-112612A
-
|
RTI-13951-33 hydrochloride
|
Others
|
Neurological Disease
|
|
RTI-13951-33 hydrochloride is a potent, selective, and brain-penetrant GPR88 agonist, with an EC50 of 25 nM in GPR88 cAMP functional assay. RTI-13951-33 hydrochloride reduces alcohol reinforcement and intake behaviors in rats.
|
-
- HY-B0637
-
|
Bezafibrate
BM15075
|
PPAR
|
Metabolic Disease
Cardiovascular Disease
|
|
Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
- HY-10232
-
|
THIP
Gaboxadol
|
GABA Receptor
|
Neurological Disease
|
|
THIP (Gaboxadol) is a selective δ-aminobutyric acid type A receptor (δ-GABAAR) agonist, functionally selective GABAAR ligand, exhibits agonism at α4β1δ, α4β3δ and weak antagonism at αβγ and α4β2δ GABAARs.
|
-
- HY-16687
-
-
- HY-13580
-
|
Budesonide
|
Glucocorticoid Receptor
|
Cancer
Inflammation/Immunology
|
|
Budesonide, an inhaled glucocortical steroid, is an orally active glucocorticoid receptor agonist. Budesonide decreases the size of lung tumors, reverses DNA hypomethylation and modulates mRNA expression of genes. Budesonide is an anti-inflammatory agent used for asthma.
|
-
- HY-123268
-
|
Ro 363
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Ro 363 is a potent and highly selective β1-adrenoceptor agonist. RO 363 is an effective inotropic stimulant, and is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility.
|
-
- HY-112612
-
|
RTI-13951-33
|
Others
|
Neurological Disease
|
|
RTI-13951-33 is a potent, selective, and brain-penetrant GPR88 agonist, with an EC50 of 25 nM in GPR88 cAMP functional assay. RTI-13951-33 reduces alcohol reinforcement and intake behaviors in rats.
|
-
- HY-131265
-
-
- HY-102091
-
|
(2R,4R)-APDC
|
mGluR
|
Neurological Disease
|
|
(2R,4R)-APDC is a selective group II metabotropic glutamate receptors (mGluRs) agonist. (2R,4R)-APDC has anticonvulsant and neuroprotective effects.
|
-
- HY-B0072
-
-
- HY-100839
-
|
(RS)-(Tetrazol-5-yl)glycine
D,L-(tetrazol-5-yl)glycine; LY 285265
|
iGluR
|
Neurological Disease
|
|
(RS)-(Tetrazol-5-yl)glycine (D,L-(tetrazol-5-yl)glycine) is a highly potent and selective N-methyl-D-aspartate (NMDA) receptor agonist. (RS)-(Tetrazol-5-yl)glycine has EC50s of 99 nM, 1.7 μM for GluN1/GluN2D and GluN1/GluN2A, respectively. (RS)-(Tetrazol-5-yl)glycine induces seizure responses and Fos in mice.
|
-
- HY-P1294A
-
-
- HY-N2037
-
|
Higenamine
Norcoclaurine
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Higenamine (Norcoclaurine), a β2-AR agonist, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine (Norcoclaurine) has anti-apoptotic effects.
|
-
- HY-12597
-
|
Quisqualic acid
L-Quisqualic acid
|
iGluR
mGluR
|
Neurological Disease
|
|
Quisqualic acid (L-Quisqualic acid), a natural analog of glutamate, is a potent and pan two subsets (iGluR and mGluR) of excitatory amino acid (EAA) agonist with an EC50 of 45 nM and a Ki of 10 nM for mGluR1R. Quisqualic acid is isolated from the fruits of Quisqualis chinensis.
|
-
- HY-15293B
-
|
JTV-519 hemifumarate
K201 hemifumarate
|
Calcium Channel
|
Cardiovascular Disease
|
|
JTV-519 hemifumarate (K201 hemifumarate) is a Ca 2+-dependent blocker of sarcoplasmic reticulum Ca 2+-stimulated ATPase (SERCA) and a partial agonist of ryanodine receptors in striated muscle. Antiarrhythmic and cardioprotective properties.
|
-
- HY-107495
-
-
- HY-108523
-
|
LG100754
UVI 2112
|
RAR/RXR
|
Metabolic Disease
|
|
LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR.
|
-
- HY-105296
-
|
Blarcamesine
AVex-73; AE-37
|
Sigma Receptor
mAChR
|
|
|
Blarcamesine (AVex-73;AE-37) is an orally bioavailable Sigma-1 receptor agonist and muscarinic receptor modulator, with anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties. Blarcamesine ameliorates neurologic impairments in a mouse model of Rett syndrome.
|
-
- HY-P0049
-
|
Argipressin
Vasopressin; Arg8-vasopressin; AVP
|
Vasopressin Receptor
|
Neurological Disease
|
|
Argipressin binds to the V1, V2, V3-vascular arginine vasopressin receptor, with a Kd value of 1.31 nM in A7r5 rat aortic smooth muscle cells for V1. Argipressin is a selective V2 agonist.
|
-
- HY-P1438A
-
|
Neuropeptide S(Rat) TFA
|
Neuropeptide Y Receptor
|
|
|
Neuropeptide S(Rat) TFA is a potent endogenous neuropeptide S receptor (NSPR) agonist (EC50=3.2 nM). Neuropeptide S(Rat) TFA increases locomotor activity and wakefulness in mice. Neuropeptide S(Rat) TFA also reduces anxiety-like behavior in mice.
|
-
- HY-P1166A
-
|
UFP-803 TFA
|
Urotensin Receptor
|
Cardiovascular Disease
|
|
UFP-803 TFA is a potent urotensin-II receptor (UT) ligand. UFP-803 TFA has lower residual agonist activity, so it may be an important tool for the investigations on the role played by the UT system in physiology and pathology.
|
-
- HY-108699
-
|
TM-N1324
|
GHSR
|
Neurological Disease
Endocrinology
|
|
TM-N1324 is an agonist of G-Protein-Coupled Receptor 39 (GPR39) with EC50s of 9 nM/5 nM in the presence of Zn 2+, and 280 nM/180 nM in the absence of Zn 2+ for human/murine GPR39.
|
-
- HY-14442
-
-
- HY-17355
-
-
- HY-N2037A
-
-
- HY-111021
-
|
ASP-4058
|
LPL Receptor
|
Inflammation/Immunology
|
|
ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
|
-
- HY-17606
-
|
Cenerimod
ACT-334441
|
LPL Receptor
|
Inflammation/Immunology
|
|
Cenerimod (ACT-334441) is a potent and orally available sphingosine 1-phosphate 1 receptor (S1P1) agonist extracted from patent WO 2016184939 A1 and WO 2011007324 A1, example 1, with an EC50 of 2.7 nM.
|
-
- HY-12498
-
|
GV-58
|
Calcium Channel
|
Neurological Disease
|
|
GV-58 is a potent, selective N- and P/Q-type Ca2+ channels agonist with EC50 of 7.21/8.81 uM for N-type/P-Q-type Ca2+ channel; 20-fold less potent CDK inhibitor activity.
|
-
- HY-130120
-
|
HWL-088
|
GPR40
|
Metabolic Disease
|
|
HWL-088 (compound 7) is a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist bearing a phenoxyacetic acid scaffold. HWL-088 significantly improves glucose tolerance in normal and diabetic models.
|
-
- HY-14648
-
-
- HY-119243
-
-
- HY-103243
-
|
TCPOBOP
|
Bcl-2 Family
|
Cancer
|
|
TCPOBOP is a constitutive androstane receptor (CAR) agonist that induces robust hepatocyte proliferation and hepatomegaly without any liver injury or tissue loss. TCPOBOP attenuates Fas-induced murine liver injury by altering Bcl-2 proteins.
|
-
- HY-18282
-
|
AZ876
|
LXR
|
Cancer
|
|
AZ876 is a potent and high-affinity LXR agonist. AZ876 displays 25-fold and 2.5-fold more potent than GW3965 (HY-10627) on human (h)LXRα and hLXRβ respectively.
|
-
- HY-129658
-
-
- HY-110120
-
|
DSR-6434
|
Toll-like Receptor (TLR)
|
Cancer
|
|
DSR-6434 is a potent and selective Toll-like receptor 7 (TLR7) agonist, with EC50s of 7.2 nM and 4.6 nM for human and mice TLR7, respectively. DSR-6434 has a strong antitumor effect.
|
-
- HY-100488
-
|
Bay 59-3074
|
Cannabinoid Receptor
|
Cancer
|
|
Bay 59-3074 is a selective cannabinoid CB1/CB2 receptor partial agonist with Ki values of 48.3 and 45.5 nM at human CB1 and CB2 receptors, respectively. Bay 59-3074 has analgesic properties.
|
-
- HY-P1298
-
|
Sauvagine
|
CRFR
|
Endocrinology
Neurological Disease
Cardiovascular Disease
|
|
Sauvagine, a 40-amino-acid neuropeptide from the skin of the frog, is a mammalian CRF agonist. Sauvagine is effective at releasing ACTH from rat pituitary cells. Sauvagine possesses a number of pharmacological actions on diuresis, the cardiovascular system and endocrine glands.
|
-
- HY-105285
-
-
- HY-129105
-
|
Clomethiazole
|
GABA Receptor
Cytochrome P450
|
Neurological Disease
|
|
Chlormethiazole is an potent and orally active GABAA agonist. Chlormethiazole inhibits cytochrome P450 isoforms: CYP2A6 and CYP2E1 in human liver microsomes. Chlormethiazole is an anticonvulsant agent and has the potential for treating convulsive status epilepticus.
|
-
- HY-105040
-
|
Pomaglumetad methionil
LY2140023 hydrate
|
mGluR
|
Neurological Disease
|
|
Pomaglumetad methionil (LY2140023 hydrate) is an oral methionine prodrug of the potent specific mGlu2/3 receptor agonist LY404039 (HY-50906). Pomaglumetad methionil is well-tolerated and has a distinct safety profile, and can be used for schizophrenia.
|
-
- HY-A0095S
-
|
Flibanserin D4
BIMT-17 D4; BIMT-17BS D4
|
5-HT Receptor
|
Neurological Disease
|
|
Flibanserin D4 is a deuterium labeled Flibanserin (BIMT-17). Flibanserin is a full agonist of the serotonin 5-HT1A receptor (Ki=1 nM) and an antagonist of 5-HT2A (49 nM).
|
-
- HY-119486
-
|
Tavapadon
PF-06649751; CVL-751
|
Dopamine Receptor
|
Neurological Disease
|
|
Tavapadon (PF-06649751; CVL-751) is an orally active and highly selective dopamine D1/D5 receptor partial agonist. Tavapadon is effective in enabling movement and reducing disability and has the potential for Parkinson's disease.
|
-
- HY-P1214
-
-
- HY-13225
-
|
Rivanicline oxalate
RJR-2403 oxalate; (E)-Metanicotine oxalate
|
nAChR
|
Neurological Disease
|
|
Rivanicline oxalate (RJR-2403 oxalate; (E)-Metanicotine oxalate) is a neuronal nicotinic receptor agonist, showing high selectivity for the α4β2 subtype (Ki=26 nM); > 1,000 fold selectivity than α7 receptors(Ki= 3.6 μM).
|
-
- HY-109083
-
|
Cilofexor
GS-9674
|
FXR
Autophagy
|
Inflammation/Immunology
|
|
Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC50 of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research.
|
-
- HY-117407
-
|
ALLO-2
|
Smo
|
Cancer
|
|
ALLO-2 is a potent drug-resistant Smoothened (Smo) mutant antagonist that inhibits Smo agonist Hh-Ag1.5-induced luciferase expression in TM3-Gli-Luc cells with IC50 of 6 nM.
|
-
- HY-14422
-
|
SR1078
|
ROR
|
Cancer
|
|
SR1078 is a selective agonist of retinoic acid receptor-related orphan receptor α/γ (RORα/RORγ). SR1078 directly binds to the ligand binding domain of RORα and RORγ and increases the transcriptional activity of these receptors, leading to stimulation of RORα/γ target gene transcription.
|
-
- HY-13956S
-
|
Pioglitazone D4
U 72107 D4
|
PPAR
Ferroptosis
|
Cancer
Metabolic Disease
|
|
Pioglitazone D4 (U 72107 D4) is a deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
|
-
- HY-13225B
-
|
Rivanicline hemioxalate
RJR-2403 hemioxalate; (E)-Metanicotine hemioxalate
|
nAChR
|
Neurological Disease
|
|
Rivanicline hemioxalate (RJR-2403 hemioxalate; (E)-Metanicotine hemioxalate) is a neuronal nicotinic receptor agonist, showing high selectivity for the α4β2 subtype (Ki=26 nM); > 1,000 fold selectivity than α7 receptors(Ki= 3.6 μM).
|
-
- HY-112813
-
|
TUG-1375
|
Others
|
Metabolic Disease
|
|
TUG-1375 is an agonist of free fatty acid receptor 2 (FFA2/GPR43), with a pKi of 6.69. TUG-1375 is inactive on FFA3, FFA4, PPARα, PPARγ, PPARδ, LXRα or LXRβ.
|
-
- HY-15293A
-
|
JTV-519 free base
K201 free base
|
Calcium Channel
|
Cardiovascular Disease
|
|
JTV-519 free base (K201 free base) is a Ca 2+-dependent blocker of sarcoplasmic reticulum Ca 2+-stimulated ATPase (SERCA) and a partial agonist of ryanodine receptors in striated muscle. Antiarrhythmic and cardioprotective properties.
|
-
- HY-103551A
-
|
LY 541850
|
mGluR
|
Neurological Disease
|
|
LY 541850 is claimed from human ionotropic and metabotropic glutamate (mGlu) receptors expressed in non-neuronal cells. LY541850 is a selective orthosteric mGlu2 agonist and mGlu3 antagonist with IC50 values of 0.161 μM and 0.038 μM, respectively.
|
-
- HY-15296
-
-
- HY-19231
-
|
DPI-3290
Org 41793
|
Opioid Receptor
|
Neurological Disease
|
|
DPI-3290 (Org 41793) is a potent and specific opioid receptors agonist with Ki values of 0.18 nM, 0.46 nM, and 0.62 nM for δ-, μ-, and κ-opioid receptors, respectively。DPI-3290 is one of a series of novel centrally acting agents with potent antinociceptive activity.
|
-
- HY-15780
-
-
- HY-108015
-
|
RO5263397
|
Others
|
Neurological Disease
|
|
RO5263397 is a potent, selective, and orally available TAAR1 agonist, with EC50s of 17 and 35 nM for human TAAR1 and rat TAAR1, respectively. RO5263397 regulates wakefulness and EEG spectral composition. Antidepressant-like effect.
|
-
- HY-15128
-
-
- HY-125976
-
|
ML233
|
Others
|
Cardiovascular Disease
|
|
ML233 is a non-peptide based potent apelin receptor (APJ) agonist (EC50=3.7 μM). ML233 displays >21-fold selective over the closely related angiotensin 1 (AT1) receptor (>79 μM).
|
-
- HY-110318
-
|
VUF11207 fumarate
|
CXCR
|
Cancer
|
|
VUF11207 fumarate (Compound 29) is a CXCR7 agonist and a high-potency CXCR7 (pKi of 8.1) ligand that induces recruitment of β-arrestin2 (pEC50 of 8.8) and subsequent internalization (pEC50 of 7.9) of CXCR7.
|
-
- HY-119163
-
-
- HY-P1091
-
|
Hemopressin (human, mouse)
|
Cannabinoid Receptor
|
Neurological Disease
|
|
Hemopressin is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin exerts antinociceptive action in inflammatory pain models.
|
-
- HY-103186
-
-
- HY-14903
-
|
Ulimorelin
TZP-101
|
GHSR
Adrenergic Receptor
|
Metabolic Disease
|
|
Ulimorelin (TZP-101) is a ghrelin receptor (GRLN) agonist with an EC50 of 29 nM and a Ki of 16 nM. Ulimorelin is a prokinetic agent and causes vasorelaxation through competitive antagonist action at α1-adrenoceptors. Ulimorelin stimulates intestinal motility and is used for malnutrition.
|
-
- HY-12585
-
|
AM-4668
|
GPR40
|
Metabolic Disease
|
|
AM-4668 is a GPR40 agonist for type 2 diabetes. EC50s of 3.6 nM and 36 nM for GPR40 in A9 cells (GPR40 IP3 assay) and CHO cells (GPR40 aequorin assay), respectively.
|
-
- HY-119744
-
|
BAY 38-7271
|
Cannabinoid Receptor
|
Neurological Disease
|
|
BAY 38-7271 is selective and highly potent and cannabinoid CB1/CB2 receptor agonist, with Kis of 1.85 nM and 5.96 nM for recombinant human CB1 receptor and CB2 receptor, respectively. BAY 38-7271 has strong neuroprotective properties.
|
-
- HY-14900
-
|
Tedalinab
GRC-10693
|
Cannabinoid Receptor
|
Inflammation/Immunology
|
|
Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment.
|
-
- HY-P1316
-
|
Ac-RYYRWK-NH2
|
Opioid Receptor
|
Neurological Disease
|
|
Ac-RYYRWK-NH2 is a potent and selective partial agonist for the nociceptin receptor (NOP), [ 3H]Ac-RYYRWK-NH2 binds to rat cortical membranes ORL1 with a Kd of 0.071 nM, but has no affinity for µ-, κ- or δ-opioid receptors.
|
-
- HY-133128
-
|
FM26
|
ROR
|
Cancer
|
|
FM26 (compound 25) is a potent and allosteric retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists with an IC50 of 264 nM. FM26 has a distinct isoxazole chemotype and effectively reduces IL-17a mRNA production in EL4 cells.
|
-
- HY-106660
-
|
BP 897
|
Dopamine Receptor
|
Neurological Disease
|
|
BP 897 is a potent and selective dopamine D3 receptor agonist, and a weak dopamine D2 receptor antagonist, with Kis of 0.92 nM and 61 nM for D3 and D2 receptors, and shows low affinities at D1 and D4 receptors (Kis, 3 and 0.3 µM, respectively).
|
-
- HY-P1090
-
|
Hemopressin(rat)
|
Cannabinoid Receptor
|
Neurological Disease
|
|
Hemopressin(rat) is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) exerts antinociceptive action in inflammatory pain models.
|
-
- HY-133024
-
|
Flumexadol
|
5-HT Receptor
|
Neurological Disease
|
|
Flumexadol is an orally active non-narcotic analgesic. Flumexadol is a selective and affinity 5-HT2C receptor agonist with a Ki of 25 nM for the (+)-enantiomer of Flumexadol, and is 40-fold selective over the 5-HT2A receptor.
|
-
- HY-121653
-
|
Flesinoxan
|
5-HT Receptor
|
Neurological Disease
|
|
Flesinoxan is a hypotensive agent and a potent, high affinity and selective 5-hydroxytryptamine1A (5-HT1A) receptor agonist with an EC50 value of 24 nM. Flesinoxan also has effective anxiolytic/antidepressant effects.
|
-
- HY-P1437
-
|
Neuropeptide S(Mouse)
|
Neuropeptide Y Receptor
|
|
|
Neuropeptide S(Mouse) is a potent endogenous neuropeptide S receptor (NPSR) agonist (EC50=3 nM). Neuropeptide S(Mouse) induces mobilization of intracellular Ca 2+. Neuropeptide S(Mouse) increases locomotor activity and wakefulness in mice. Neuropeptide S(Mouse) also reduces anxiety-like behavior in mice.
|
-
- HY-P1319
-
|
Nociceptin(1-7)
|
Opioid Receptor
|
Inflammation/Immunology
|
|
Nociceptin (1-7) is the N-terminal bioactive fragment of nociceptin (HY-P0183). Nociceptin (1-7) is a potent ORL1 (NOP) receptor agonist with antinociceptive activity. Nociceptin (1-7) combines with nociceptin reduces hyperalgesia in vivo.
|
-
- HY-P1072
-
|
PHM-27 (human)
|
CGRP Receptor
|
Metabolic Disease
Cardiovascular Disease
|
|
PHM-27 (human) is a human prepro-vasoactive intestinal polypeptide (27 amino acid). PHM-27 (human) is a potent the human calcitonin receptor agonist with an EC50 of 11 nM. PHM-27 (human) efficiently enhances glucose-induced insulin secretion from beta cells by an autocrine mechanism.
|
-
- HY-15778A
-
-
- HY-136657
-
|
SC-43
|
STAT
Phosphatase
Apoptosis
|
Cancer
|
|
SC-43, a Sorafenib derivative, is a potent and orally active SHP-1 (PTPN6) agonist. SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis. SC-43 has anti-fibrotic and anticancer effects.
|
-
- HY-P1316A
-
|
Ac-RYYRWK-NH2 TFA
|
Opioid Receptor
|
Neurological Disease
|
|
Ac-RYYRWK-NH2 is a potent and selective partial agonist for the nociceptin receptor (NOP), [ 3H]Ac-RYYRWK-NH2 binds to rat cortical membranes ORL1 with a Kd of 0.071 nM, but has no affinity for µ-, κ- or δ-opioid receptors.
|
-
- HY-136577
-
-
- HY-113854
-
-
- HY-10349
-
|
WAY-100635
|
5-HT Receptor
Dopamine Receptor
|
Neurological Disease
|
|
WAY-100635 is a potent and selective 5-HT1A Receptor antagonist with a pIC50 of 8.87, an apparent pA2 of 9.71.
WAY-100635 is a potent and selective 5-hydroxytryptamine 1A (5-HT1A) receptor antagonist with an IC50 value of 0.91 nM and Ki value of 0.39 nM. WAY-100635 has pIC50 values for 5-HT1A and α1-adrenergic receptors of 8.9 and 6.6, respectively. WAY-100635 is also a potent dopamine D4 receptor agonist.
|
-
- HY-120528A
-
-
- HY-110302
-
|
6'-GNTI dihydrochloride
|
Opioid Receptor
|
Neurological Disease
|
|
6'-GNTI dihydrochloride, a κ-opioid receptor (KOR) agonist, displays bias toward the activation of G protein-mediated signaling over β-arrestin2 recruitment. 6'-GNTI 6'-GNTI dihydrochloride only activates the Akt pathway in striatal neurons.
|
-
- HY-P1298A
-
|
Sauvagine TFA
|
CRFR
|
Endocrinology
Neurological Disease
Cardiovascular Disease
|
|
Sauvagine TFA, a 40-amino-acid neuropeptide from the skin of the frog, is a mammalian CRF agonist. Sauvagine TFA is effective at releasing ACTH from rat pituitary cells. Sauvagine TFA possesses a number of pharmacological actions on diuresis, the cardiovascular system and endocrine glands.
|
-
- HY-P1341
-
-
- HY-100999
-
-
- HY-120528
-
-
- HY-13221
-
-
- HY-P1214A
-
-
- HY-103697
-
|
Gardiquimod
|
Toll-like Receptor (TLR)
HIV
|
Cancer
Infection
|
|
Gardiquimod, an imidazoquinoline analog, is a TLR7/8 agonist. Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 when used at concentrations below 10 μM.
|
-
- HY-N7032
-
-
- HY-15701B
-
|
ADH-503
(Z)-Leukadherin-1 choline
|
Complement System
|
Cancer
|
|
ADH-503 ((Z)-Leukadherin-1 choline) is an orally active and allosteric CD11b agonist. ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses.
|
-
- HY-136578
-
-
- HY-10426
-
|
XCT790
|
Estrogen Receptor/ERR
Autophagy
|
Cancer
|
|
XCT-790 is a potent and selective inverse agonist for ERRα with an IC50 value of 0.37 μM. XCT-790 induces cell death in chemotherapeutic resistant cancer cells. XCT-790 (Compound 12) is inactive against ERRγ and the estrogen receptors ERα and ERβ.
|
-
- HY-W020468
-
|
Linopirdine
DuP 996
|
Potassium Channel
TRP Channel
|
Neurological Disease
|
|
Linopirdine (DuP 996) is an orally active, selective M-type K + current (IM; Kv7; KCNQ Channels) inhibitor with an IC50 of 2.4 μM. Linopirdine is a TRPV1 agonist. Linopirdine, a putative cognition enhancing drug, increases acetylcholine release in rat brain tissue.
|
-
- HY-P1416
-
|
Foxy-5
|
Wnt
|
Cancer
|
|
Foxy-5 is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 is a WNT5A agonist and effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.
|
-
- HY-135750
-
|
VAF347
|
Aryl Hydrocarbon Receptor
|
Inflammation/Immunology
|
|
VAF347 is a cell permeable and highly affinity aryl hydrocarbon receptor (AhR) agonist and induces AhR signaling. VAF347 inhibits the development of CD14 +CD11b + monocytes from granulo-monocytic (GM stage) precursors. VAF347 has anti-inflammatory effects.
|
-
- HY-P0227
-
|
SHU 9119
|
Others
|
Metabolic Disease
|
|
SHU 9119 is a potent human melanocortin 3 and 4 receptors (MC3/4R) antagonist and a partial MC5R agonist; with IC50 values of 0.23, 0.06, and 0.09 nM for human MC3R, MC4R and MC5R, respectively.
|
-
- HY-124136
-
|
WYC-209
|
RAR/RXR
Apoptosis
Autophagy
|
Cancer
|
|
WYC-209, a synthetic retinoid, is a retinoic acid receptor (RAR) agonist. WYC-209 induces apoptosis primarily via the caspase 3 pathway (IC50=0.19 μM for inmalignant murine melanoma TRCs), and has long-term effects with little toxicity.
|
-
- HY-109035
-
|
Inarigivir soproxil
SB9200
|
HCV
|
Infection
|
|
Inarigivir soproxil is an agonist of innate immunity and shows potent antiviral activity against resistant hepatitis C virus (HCV) variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems.
|
-
- HY-124899
-
|
Hh-Ag1.5
SAg1.5
|
Hedgehog
|
Metabolic Disease
|
|
Hh-Ag1.5 (SAg1.5) is a potent Hedgehog (Hh) agonist with an EC50 of 1 nM. Hh-Ag1.5 mediated reprogramming breaks the quiescence of noninjured liver stem cells for rescuing liver failure.
|
-
- HY-12752
-
|
Alimemazine
Trimeprazine
|
Others
|
Inflammation/Immunology
Neurological Disease
|
|
Alimemazine is a phenothiazine derivative that is generally used as an antipruritic agent and also a hemagglutinin (HA)-receptor antagonist.Alimemazine (Trimeprazine) is also acts as a partial agonist against the histamine H1 receptor (H1R) and other GPCRs. Alimemazine displays sedative, antiserotonin, antispasmodic, and antiemetic properties.
|
-
- HY-100450
-
-
- HY-12150
-
|
CCMI
|
nAChR
|
Neurological Disease
|
|
CCMI is a potent and selective α7 nAChR-positive allosteric modulator, does not bind to or activate α7 nAChRs via the orthosteric site, and causes significant positive modulation of agonist-induced currents at α7 nAChRs. CCMI has potential in CNS diseases with cognitive dysfunction.
|
-
- HY-101173
-
